**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10–Q**

☒   **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **March 31, 2024**

**or**

☐   **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from [               ] to [                ]**

**Commission file number:** 000-55768

|  |  |  |
| --- | --- | --- |
| **HealthLynked Corp.** | | |
| (Exact name of registrant as specified in its charter) | | |
|  |  |  |
| **Nevada** |  | **47-1634127** |
| (State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.) |
|  |  |  |
| **1265 Creekside Parkway, Suite 302, Naples FL 34108** | | |
| (Address of principal executive offices) | | |
|  | | |
| **(800) 928-7144** | | |
| (Registrant’s telephone number, including area code) | | |
|  | | |
|  | | |
| (Former name, former address and former fiscal year, if changed since last report) | | |

Securities registered pursuant to Section 12(b) of the Act: **None.**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒  No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒  No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

|  |  |  |  |
| --- | --- | --- | --- |
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

As of May 15, 2024, there were 281,942,151 shares of the issuer’s common stock, par value $0.0001, outstanding.

**TABLE OF CONTENTS**

|  |  |  |
| --- | --- | --- |
|  |  | **PAGE NO.** |
|  |  |  |
| PART I | [FINANCIAL INFORMATION](#a_001) | 1 |
| Item 1 | [Financial Statements (Unaudited)](#a_002) | 1 |
| Item 2 | [Management’s Discussion and Analysis of Financial Condition and Results of Operations](#a_003) | 35 |
| Item 3 | [Quantitative and Qualitative Disclosures about Market Risk](#a_004) | 41 |
| Item 4 | [Controls and Procedures](#a_005) | 41 |
|  |  |  |
| Part II | [OTHER INFORMATION](#a_006) | 42 |
| Item 1 | [Legal Proceedings](#a_007) | 42 |
| Item 1A | [Risk Factors](#a_008) | 42 |
| Item 2 | [Unregistered Sales of Equity Securities and Use of Proceeds](#a_009) | 42 |
| Item 3 | [Defaults upon Senior Securities](#a_010) | 43 |
| Item 4 | [Mine Safety Disclosure](#a_011) | 43 |
| Item 5 | [Other Information](#a_012) | 43 |
| Item 6 | [Exhibits](#a_013) | 43 |

i

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**HEALTHLYNKED CORP.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| **ASSETS** |  | ***(Unaudited)*** | |  |  |  | |  |
| **Current Assets** |  |  | |  |  |  | |  |
| Cash |  | $ | 23,491 |  |  | $ | 247,222 |  |
| Accounts receivable, net of allowance for doubtful accounts of $-0- and $-0- as of March 31, 2024 and December 31, 2023, respectively |  |  | 33,620 |  |  |  | 20,861 |  |
| Inventory, net |  |  | 136,205 |  |  |  | 133,222 |  |
| Prepaid expenses and other current assets |  |  | 40,016 |  |  |  | 55,210 |  |
| Contingent sale consideration receivable, current portion |  |  | 1,663,163 |  |  |  | 199,645 |  |
| Total Current Assets |  |  | 1,896,495 |  |  |  | 656,160 |  |
|  |  |  |  |  |  |  |  |  |
| Property and equipment, net of accumulated depreciation of $550,531 and $521,062 as of March 31, 2024 and December 31, 2023, respectively |  |  | 263,884 |  |  |  | 290,755 |  |
| Intangible assets, net of accumulated amortization of $315,730 and  $258,690 as of March 31, 2024 and December 31, 2023, respectively |  |  | 826,808 |  |  |  | 883,848 |  |
| Right of use lease assets |  |  | 853,525 |  |  |  | 935,812 |  |
| Deposits, long term portion |  |  | 50,047 |  |  |  | 50,047 |  |
| Contingent sale consideration receivable, long term portion |  |  | --- |  |  |  | 1,463,518 |  |
|  |  |  |  |  |  |  |  |  |
| Total Assets |  | $ | 3,890,759 |  |  | $ | 4,280,140 |  |
|  |  |  |  |  |  |  |  |  |
| **LIABILITIES AND SHAREHOLDERS’ EQUITY** |  |  |  |  |  |  |  |  |
| **Current Liabilities** |  |  |  |  |  |  |  |  |
| Accounts payable, accrued expenses and other current liabilities |  | $ | 705,124 |  |  | $ | 614,178 |  |
| Contract liabilities |  |  | 331,440 |  |  |  | 271,774 |  |
| Lease liability, current portion |  |  | 332,692 |  |  |  | 326,033 |  |
| Notes payable and other amounts due to related party, net of unamortized original issue discount of $281,579 and $34,834 as of March 31, 2024 and December 31, 2023, respectively |  |  | 718,642 |  |  |  | 471,742 |  |
| Notes payable, current portion, net of unamortized original issue discount of $104,288 and $166,487 as of March 31, 2024 and December 31, 2023, respectively |  |  | 462,847 |  |  |  | 584,323 |  |
| Indemnification liability |  |  | 143,974 |  |  |  | 143,974 |  |
| Total Current Liabilities |  |  | 2,694,719 |  |  |  | 2,412,024 |  |
|  |  |  |  |  |  |  |  |  |
| **Long-Term Liabilities** |  |  |  |  |  |  |  |  |
| Lease liability, long-term portion |  |  | 524,546 |  |  |  | 613,386 |  |
| Government notes payable, long-term portion |  |  | 450,000 |  |  |  | 450,000 |  |
|  |  |  |  |  |  |  |  |  |
| Total Liabilities |  |  | 3,669,265 |  |  |  | 3,475,410 |  |
|  |  |  |  |  |  |  |  |  |
| Commitments and contingencies (Note 14) |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |
| **Shareholders’ Equity** |  |  |  |  |  |  |  |  |
| Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 281,064,958 and 275,964,958 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively |  |  | 28,107 |  |  |  | 27,597 |  |
| Series B convertible preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 2,750,000 and 2,750,000 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively |  |  | 2,750 |  |  |  | 2,750 |  |
| Common stock issuable, $0.0001 par value; 1,055,536 and 2,764,352 as of March 31, 2024 and December 31, 2023, respectively |  |  | 54,570 |  |  |  | 281,682 |  |
| Additional paid-in capital |  |  | 43,556,921 |  |  |  | 42,525,837 |  |
| Accumulated deficit |  |  | (43,420,854 | ) |  |  | (42,033,136 | ) |
| Total Shareholders’ Equity |  |  | 221,494 |  |  |  | 804,730 |  |
|  |  |  |  |  |  |  |  |  |
| Total Liabilities and Shareholders’ Equity |  | $ | 3,890,759 |  |  | $ | 4,280,140 |  |

See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements

1

**HEALTHLYNKED CORP.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(UNAUDITED)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| **Revenue** |  |  | |  |  |  | |  |
| Patient service revenue, net |  | $ | 963,621 |  |  | $ | 1,700,281 |  |
| Subscription revenue |  |  | 7,628 |  |  |  | 16,299 |  |
| Product revenue |  |  | 32,983 |  |  |  | 38,574 |  |
| Total revenue |  |  | 1,004,232 |  |  |  | 1,755,154 |  |
|  |  |  |  |  |  |  |  |  |
| **Operating Expenses and Costs** |  |  |  |  |  |  |  |  |
| Practice salaries and benefits |  |  | 583,156 |  |  |  | 963,657 |  |
| Other practice operating expenses |  |  | 482,583 |  |  |  | 624,247 |  |
| Cost of product revenue |  |  | 30,579 |  |  |  | 32,060 |  |
| Selling, general and administrative expenses |  |  | 999,443 |  |  |  | 1,103,748 |  |
| Depreciation and amortization |  |  | 86,509 |  |  |  | 88,077 |  |
| Total Operating Expenses and Costs |  |  | 2,182,270 |  |  |  | 2,811,789 |  |
|  |  |  |  |  |  |  |  |  |
| Loss from operations |  |  | (1,178,038 | ) |  |  | (1,056,635 | ) |
|  |  |  |  |  |  |  |  |  |
| **Other Income (Expenses)** |  |  |  |  |  |  |  |  |
| Loss on extinguishment of debt |  |  | (96,660 | ) |  |  | (44,763 | ) |
| Amortization of original issue discounts on notes payable |  |  | (108,265 | ) |  |  | (63,360 | ) |
| Change in fair value of contingent acquisition consideration |  |  | 76 |  |  |  | (1,706 | ) |
| Interest expense and other |  |  | (4,831 | ) |  |  | (11,381 | ) |
| Total other income (expenses) |  |  | (209,680 | ) |  |  | (121,210 | ) |
|  |  |  |  |  |  |  |  |  |
| Loss from continuing operations before provision for income taxes |  |  | (1,387,718 | ) |  |  | (1,177,845 | ) |
|  |  |  |  |  |  |  |  |  |
| Provision for income taxes |  |  | --- |  |  |  | --- |  |
|  |  |  |  |  |  |  |  |  |
| Loss from continuing operations |  |  | (1,387,718 | ) |  |  | (1,177,845 | ) |
|  |  |  |  |  |  |  |  |  |
| **Discontinued operations (Note 4)** |  |  |  |  |  |  |  |  |
| Loss from operations of discontinued operations |  |  | --- |  |  |  | (44,289 | ) |
| Gain from disposal of discontinued operations |  |  | --- |  |  |  | 2,674,069 |  |
| Gain on discontinued operations |  |  | --- |  |  |  | 2,629,780 |  |
|  |  |  |  |  |  |  |  |  |
| Net income (loss) |  | $ | (1,387,718 | ) |  | $ | 1,451,935 |  |
|  |  |  |  |  |  |  |  |  |
| Loss per share from continuing operations, basic and diluted: |  |  |  |  |  |  |  |  |
| Basic |  | $ | (0.00 | ) |  | $ | (0.00 | ) |
| Fully diluted |  |  | (0.00 | ) |  |  | (0.00 | ) |
|  |  |  |  |  |  |  |  |  |
| Gain (loss) on discontinued operations, basic and diluted: |  |  |  |  |  |  |  |  |
| Basic |  | $ | 0.00 |  |  | $ | 0.01 |  |
| Fully diluted |  |  | 0.00 |  |  |  | 0.01 |  |
|  |  |  |  |  |  |  |  |  |
| Net loss per share, basic and diluted: |  |  |  |  |  |  |  |  |
| Basic |  | $ | (0.00 | ) |  | $ | 0.01 |  |
| Fully diluted |  |  | (0.00 | ) |  |  | 0.01 |  |
|  |  |  |  |  |  |  |  |  |
| Weighted average number of common shares: |  |  |  |  |  |  |  |  |
| Basic |  |  | 280,484,268 |  |  |  | 257,131,222 |  |
| Fully diluted |  |  | 280,484,268 |  |  |  | 257,131,222 |  |

See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements

2

**HEALTHLYNKED CORP.**

**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY**

**THREE MONTHS ENDED MARCH 31, 2024 AND 2023**

**(UNAUDITED)**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Number of Shares** | | | | | |  |  |  | |  |  |  | |  |  | **Common** | |  |  | **Additional** | |  |  |  | |  |  | **Total** | |  |
|  |  | **Common** | |  |  | **Preferred** | |  |  | **Common** | |  |  | **Preferred** | |  |  | **Stock** | |  |  | **Paid-in** | |  |  | **Accumulated** | |  |  | **Shareholders’** | |  |
|  |  | **Stock** | |  |  | **Stock** | |  |  | **Stock** | |  |  | **Stock** | |  |  | **Issuable** | |  |  | **Capital** | |  |  | **Deficit** | |  |  | **Equity** | |  |
|  |  | ***(#)*** | |  |  | ***(#)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |  | ***($)*** | |  |
| **Balance at December 31, 2023** |  |  | **275,964,958** |  |  |  | **2,750,000** |  |  |  | **27,597** |  |  |  | **2,750** |  |  |  | **281,682** |  |  |  | **42,525,837** |  |  |  | **(42,033,136** | **)** |  |  | **804,730** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sales of common stock |  |  | 5,100,000 |  |  |  |  |  |  |  | 510 |  |  |  |  |  |  |  | --- |  |  |  | 255,413 |  |  |  |  |  |  |  | 255,923 |  |
| Fair value of warrants allocated to proceeds of common stock |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 99,077 |  |  |  | --- |  |  |  | 99,077 |  |
| Fair value of warrants allocated to proceeds of related party debt |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 209,943 |  |  |  | --- |  |  |  | 209,943 |  |
| Fair value of beneficial conversion feature allocated to proceeds of related party debt |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 146,405 |  |  |  | --- |  |  |  | 146,405 |  |
| Consultant and director fees payable with common shares and warrants |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 43,437 |  |  |  |  |  |  |  | --- |  |  |  | 43,437 |  |
| Shares and options issued to employees |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | (270,549 | ) |  |  | 320,246 |  |  |  | --- |  |  |  | 49,697 |  |
| Net loss |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | (1,387,718 | ) |  |  | (1,387,718 | ) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Balance at March 31, 2024** |  |  | **281,064,958** |  |  |  | **2,750,000** |  |  |  | **28,107** |  |  |  | **2,750** |  |  |  | **54,570** |  |  |  | **43,556,921** |  |  |  | **(43,420,854** | **)** |  |  | **221,494** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Balance at December 31, 2022** |  |  | **255,940,389** |  |  |  | **2,750,000** |  |  |  | **25,594** |  |  |  | **2,750** |  |  |  | **225,584** |  |  |  | **41,081,455** |  |  |  | **(41,020,933** | **)** |  |  | **314,450** |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sales of common stock pursuant to Standby Equity Purchase Agreement |  |  | 225,000 |  |  |  | --- |  |  |  | 22 |  |  |  | --- |  |  |  | --- |  |  |  | 18,743 |  |  |  | --- |  |  |  | 18,765 |  |
| Other sales of common stock |  |  | 2,000,000 |  |  |  |  |  |  |  | 200 |  |  |  |  |  |  |  | --- |  |  |  | 125,998 |  |  |  |  |  |  |  | 126,198 |  |
| Fair value of warrants allocated to proceeds of common stock |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 73,802 |  |  |  | --- |  |  |  | 73,802 |  |
| Fair value of warrants allocated to proceeds of related party debt |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 95,393 |  |  |  | --- |  |  |  | 95,393 |  |
| Consultant and director fees payable with common shares and warrants |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 54,972 |  |  |  |  |  |  |  | --- |  |  |  | 54,972 |  |
| Shares and options issued to employees |  |  | 987,500 |  |  |  | --- |  |  |  | 99 |  |  |  | --- |  |  |  | (34,200 | ) |  |  | 67,229 |  |  |  | --- |  |  |  | 33,128 |  |
| Net income |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | 1,451,935 |  |  |  | 1,451,935 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Balance at March 31, 2023** |  |  | **259,152,889** |  |  |  | **2,750,000** |  |  |  | **25,915** |  |  |  | **2,750** |  |  |  | **246,356** |  |  |  | **41,462,620** |  |  |  | **(39,568,998** | **)** |  |  | **2,168,643** |  |

See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements

3

**HEALTHLYNKED CORP.**

**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**

**(UNAUDITED)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| **Cash Flows from Operating Activities** |  |  | |  |  |  | |  |
| Net income (loss) |  | $ | (1,387,718 | ) |  | $ | 1,451,935 |  |
| Loss from discontinued operations |  |  | --- |  |  |  | 44,289 |  |
| Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |  |
| Gain from disposal of discontinued operations |  |  | --- |  |  |  | (2,674,069 | ) |
| Depreciation and amortization |  |  | 86,509 |  |  |  | 88,077 |  |
| Stock based compensation, including amortization of deferred equity compensation |  |  | 93,133 |  |  |  | 88,101 |  |
| Amortization of debt discount |  |  | 108,265 |  |  |  | 63,360 |  |
| Loss on extinguishment of debt |  |  | 96,660 |  |  |  | 44,763 |  |
| Change in fair value of contingent acquisition consideration |  |  | (76 | ) |  |  | 1,706 |  |
| Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |
| Accounts receivable |  |  | (12,760 | ) |  |  | 811 |  |
| Inventory |  |  | (2,983 | ) |  |  | (97 | ) |
| Prepaid expenses and other current assets |  |  | 15,194 |  |  |  | 56,566 |  |
| Right of use lease assets |  |  | 82,287 |  |  |  | 334,157 |  |
| Accounts payable and accrued expenses |  |  | 89,149 |  |  |  | (219,064 | ) |
| Lease liability |  |  | (82,181 | ) |  |  | (333,881 | ) |
| Contract liabilities |  |  | 59,666 |  |  |  | 996 |  |
| Net cash used in continuing operating activities |  |  | (854,855 | ) |  |  | (1,052,350 | ) |
| Net cash used in discontinued operating activities |  |  | --- |  |  |  | (47,163 | ) |
| Net cash used in operating activities |  |  | (854,855 | ) |  |  | (1,099,513 | ) |
|  |  |  |  |  |  |  |  |  |
| **Cash Flows from Investing Activities** |  |  |  |  |  |  |  |  |
| Proceeds from sale of discontinued operations |  |  | --- |  |  |  | 781,381 |  |
| Acquisition of property and equipment |  |  | (2,598 | ) |  |  | --- |  |
| Net cash provided by (used in) continuing investing activities |  |  | (2,598 | ) |  |  | 781,381 |  |
| Net cash used in discontinued investing activities |  |  | --- |  |  |  | --- |  |
| Net cash provided by (used in) investing activities |  |  | (2,598 | ) |  |  | 781,381 |  |
|  |  |  |  |  |  |  |  |  |
| **Cash Flows from Financing Activities** |  |  |  |  |  |  |  |  |
| Proceeds from sale of common stock |  |  | 355,000 |  |  |  | 200,000 |  |
| Proceeds from related party notes payable |  |  | 500,000 |  |  |  | 455,000 |  |
| Proceeds from third party notes payable |  |  | --- |  |  |  | 100,000 |  |
| Repayment of related party notes payable |  |  | (37,602 | ) |  |  | (229,500 | ) |
| Repayment of third party notes payable |  |  | (183,676 | ) |  |  | (200,593 | ) |
| Net cash provided by continuing financing activities |  |  | 633,722 |  |  |  | 324,907 |  |
| Net cash provided by discontinued financing activities |  |  | --- |  |  |  | --- |  |
| Net cash provided by financing activities |  |  | 633,722 |  |  |  | 324,907 |  |
|  |  |  |  |  |  |  |  |  |
| **Net increase (decrease) in cash** |  |  | **(223,731** | **)** |  |  | **6,775** |  |
| Cash, beginning of period |  |  | 247,222 |  |  |  | 61,891 |  |
|  |  |  |  |  |  |  |  |  |
| **Cash, end of period** |  | **$** | **23,491** |  |  | **$** | **68,666** |  |
|  |  |  |  |  |  |  |  |  |
| Supplemental disclosure of cash flow information: |  |  |  |  |  |  |  |  |
| Cash paid during the period for interest |  | $ | 6,579 |  |  | $ | 3,272 |  |
| Cash paid during the period for income tax |  | $ | --- |  |  | $ | --- |  |
| Schedule of non-cash investing and financing activities: |  |  |  |  |  |  |  |  |
| Common stock issuable issued during period |  | $ | --- |  |  | $ | 34,105 |  |
| Fair value of options issued in satisfaction of common stock issuable |  |  | 270,549 |  |  |  | --- |  |
| Fair value of warrants allocated to proceeds of related party notes payable |  | $ | 209,943 |  |  | $ | 95,393 |  |
| Fair value of beneficial conversion feature allocated to proceeds of related party notes payable |  | $ | 146,405 |  |  | $ | --- |  |
| Net carrying value of equity liabilities (assets) written off |  | $ | --- |  |  | $ | 2,350 |  |
| Proceeds from sale of common stock under Standby Equity Purchase Agreement applied to note payable balance |  | $ | --- |  |  | $ | 18,743 |  |
| Incremental fair value of convertible note payable to related party resulting from refinancing |  | $ | 33,121 |  |  | $ | -- |  |
| Note payable to related party balance classified as accrued interest |  | $ | 1,875 |  |  | $ | -- |  |

See the accompanying notes to these Unaudited Condensed Consolidated Financial Statements

4

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 1 – BUSINESS AND BUSINESS PRESENTATION**

HealthLynked Corp. (the “Company”) was incorporated in the State of Nevada on August 4, 2014. On September 2, 2014, the Company filed Amended and Restated Articles of Incorporation with the Secretary of State of Nevada setting the total number of authorized shares at 250,000,000 shares, which included up to 230,000,000 shares of common stock and 20,000,000 shares of “blank check” preferred stock. On February 5, 2018, the Company filed an Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of Nevada to increase the number of authorized shares of common stock to 500,000,000 shares.

The Company currently operates in three distinct divisions: the Health Services Division, the Digital Healthcare Division, and the Medical Distribution Division. The Health Services Division is comprised of the operations of (i) Naples Women’s Center (“NWC”), a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology) and General Practice, (ii) Naples Center for Functional Medicine (“NCFM”), a Functional Medical Practice engaged in improving the health of its patients through individualized and integrative health care, (iii) Bridging the Gap Physical Therapy (“BTG”), a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, and (iv) Aesthetic Enhancements Unlimited (“AEU”), a patient service facility specializing in minimally and non-invasive cosmetic services acquired by the Company in May 2022. The Digital Healthcare Division develops and operates an online personal medical information and record archive system, the “HealthLynked Network,” which enables patients and doctors to keep track of medical information via the Internet in a cloud-based system. The Medical Distribution Division is comprised of the operations of MedOffice Direct LLC (“MOD”), a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States.

During October 2022, the Company’s Board of Directors (the “Board”) approved a plan to sell the Company’s ACO/MSO (Accountable Care Organization / Managed Service Organization) Division, comprised of the operations of Cura Health Management LLC (“CHM”) and its subsidiary ACO Health Partners LLC (“AHP”), which operates an Accountable Care Organization (“ACO”) and Managed Service Organization (“MSO”) that assists physician practices in providing coordinated and more efficient care to patients via the Medicare Shared Savings Program (“MSSP”) as administered by the Centers for Medicare and Medicaid Services (the “CMS”). On January 17, 2023, the Company entered into an Agreement and Plan of Merger (the “AHP Merger Agreement”) pursuant to which PBACO Holding, LLC, an operator of ACOs, (“Buyer”) agreed to buy, and the Company agreed to sell, AHP. See Note 4, “Discontinued Operations,” for additional information.

These unaudited condensed consolidated financial statements reflect all adjustments including normal recurring adjustments, which, in the opinion of management, are necessary to present fairly the financial position, results of operations and cash flows for the periods presented in accordance with the accounting principles generally accepted in the United States of America (“GAAP”). These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto for the years ended December 31, 2023 and 2022, respectively, which are included in the Company’s Form 10-K, filed with the United States Securities and Exchange Commission (the “Commission”) on April 1, 2024. The Company assumes that the users of the interim financial information herein have read, or have access to, the audited consolidated financial statements for the preceding period, and that the adequacy of additional disclosure needed for a fair presentation may be determined in that context. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of results for the entire year ending December 31, 2024.

On a consolidated basis, the Company’s operations are comprised of the parent company, HealthLynked Corp., and its five subsidiaries: NWC, NCFM, BTG, MOD and AEU. Results through January 17, 2023 also include operations of AHP, which was sold, and CHM, which was discontinued, both effective as of January 17, 2023. All significant intercompany transactions and balances have been eliminated upon consolidation. In addition, certain amounts in the prior periods’ consolidated financial statements have been reclassified to conform to the current period presentation.

Uncertainty Due to Geopolitical Events

Due to the Hamas-Israel and Russia-Ukraine conflicts, there has been uncertainty and disruption in the global economy. Although these events did not have a direct material adverse impact on the Company’s financial results for the three months ended March 31, 2024, at this time the Company is unable to fully assess the aggregate impact the Hamas-Israel and Russia-Ukraine conflicts will have on its business due to various uncertainties, which include, but are not limited to, the duration of the conflicts, the conflicts’ effect on the economy, the impact on the Company’s businesses and actions that may be taken by governmental authorities related to the conflicts.

5

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES**

A summary of the significant accounting policies applied in the presentation of the accompanying condensed consolidated financial statements follows:

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in conformity with GAAP. All amounts referred to in the notes to the condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates. Significant estimates include assumptions about fair valuation of acquired intangible assets; cash flow and fair value assumptions associated with measurements of contingent sale consideration receivable, contingent acquisition consideration payable, and impairment of intangible assets; valuation of inventory; collection of accounts receivable; the valuation and recognition of stock-based compensation expense; valuation allowance for deferred tax assets; and borrowing rate consideration for right-of-use (“ROU”) lease assets including related lease liability and useful life of fixed assets.

Revenue Recognition

*Patient service revenue*

Patient service revenue is earned for patient services provided to patients at our NWC facility, functional medicine services provided to patients at our NCFM facility, and physical therapy services provided to patients at our BTG facility. Patient service revenue is reported at the amount that reflects the consideration to which the Company expects to be entitled in exchange for providing patient care. These amounts are due from patients and third-party payors (including health insurers and government programs) and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Company bills patients and third-party payors within days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Company. Revenue for performance obligations satisfied over time includes revenue from NCFM annual access contracts (called the Medical Membership and Concierge Program prior to October 1, 2023 and Optimal Health 365 Access Plan thereafter), NWC annual administration fees, and BTG physical therapy bundles. Revenue from NCFM Medical Memberships and Concierge contracts and NWC annual administration fees, which include bundled products and services that have substantially the same pattern of transfer to the customer, is recognized over the period of delivery, which is the same as the period of the contract (typically, one year). Revenue from prepaid BTG physical therapy bundles, for which performance obligations are satisfied over time as visits are incurred, is recognized based on actual visits incurred in relation to total expected visits. At inception of such contracts, the Company recognizes contract liabilities for the value of services to be provided and, where applicable, contract assets for recoverable amounts incurred to obtain a customer contract that would not have incurred if the contract had not been obtained. The Company believes that these methods provide a faithful depiction of the transfer of services over the term of the performance obligations based on the inputs needed to satisfy the obligation.

Revenue for performance obligations satisfied at a point in time, which includes all patient service revenue other than NCFM annual access contracts, NWC annual administration fees, and BTG physical therapy bundles, is recognized when goods or services are provided at the time of the patient visit, and at which time the Company is not required to provide additional goods or services to the patient.

6

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

The Company determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Company’s policy, and/or implicit price concessions provided to uninsured patients. Estimates of contractual adjustments and discounts require significant judgment and are based on the Company’s current contractual agreements, its discount policies, and historical experience. The Company determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. There were no material changes during the three months ended March 31, 2024 or 2023 to the judgments applied in determining the amount and timing of patient service revenue.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

|  |  |  |
| --- | --- | --- |
|  | ● | Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates; |

|  |  |  |
| --- | --- | --- |
|  | ● | Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member. |

|  |  |  |
| --- | --- | --- |
|  | ● | Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates. |

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Company’s compliance with these laws and regulations, and it is not possible to determine the impact, if any, such claims or penalties would have upon the Company. In addition, the contracts the Company has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company’s historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known, or as years are settled or are no longer subject to such audits, reviews, and investigations.

The Company also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Company estimates the transaction price for patients with deductibles and coinsurance and for those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. Patient services provided by NCFM, BTG and AEU are provided on a cash basis and not submitted through third party insurance providers.

7

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

*Product and Other Revenue*

Revenue is derived from the distribution of medical products that are sourced from a third party. The Company recognizes revenue at a point in time when title transfers to customers and the Company has no further obligation to provide services related to such products, which occurs when the product ships. The Company is the principal in its revenue transactions and as a result revenue is recorded on a gross basis. The Company has determined that it controls the ability to direct the use of the product provided prior to transfer to a customer, is primarily responsible for fulfilling the promise to provide the product to its customer, has discretion in establishing prices, and ultimately controls the transfer of the product to the customer. Shipping and handling costs billed to customers are recorded in revenue. Contract liabilities related to product revenue are recognized when payment is received but for which the Company has not met its product fulfillment performance obligation.

Sales are made inclusive of sales tax, where such sales tax is applicable. Sales tax is applicable on sales made in the state of Florida, where the Company has physical nexus. The Company has determined that it does not have economic nexus in any other states. The Company does not sell products outside of the United States.

The Company maintains a return policy that allows customers to return a product within a specified period of time prior to and subsequent to the expiration date of the product. The Company analyzes the need for a product return allowance at the end of each period based on eligible products.

Cash and Cash Equivalents

For financial statement purposes, the Company considers all highly liquid investments with original maturities of six months or less to be cash and cash equivalents. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company had $-0- and $-0- in cash balances in excess of the FDIC insured limit as of March 31, 2024 and December 31, 2023, respectively.

Accounts Receivable

Trade receivables related to NWC services billed to third party payors are carried at the estimated collectible amount. Trade credit is generally extended on a short-term basis; thus trade receivables do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past collectability of the insurance companies, government agencies, and customers’ accounts receivable during the related period which generally approximates 61% of total billings. Trade accounts receivable are recorded at this net amount. As of March 31, 2024 and December 31, 2023, the Company’s gross patient services accounts receivable were $40,295 and $34,481, respectively, and net patient services accounts receivable were $33,620 and $20,861, respectively, based upon net reporting of accounts receivable. As of March 31, 2024 and December 31, 2023, the Company’s allowance for doubtful accounts was $-0- and $-0-, respectively.

Other Comprehensive Income

The Company does not have any activity that results in Other Comprehensive Income.

Leases

Upon transition under ASU 2016-02, the Company elected the suite of practical expedients as a package applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases. For new leases, the Company will determine if an arrangement is or contains a lease at inception. Leases are included as ROU assets within other assets and ROU liabilities within accrued expenses and other liabilities and within other long-term liabilities on the Company’s consolidated balance sheets.

ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term. See Note 8 for more complete details on balances as of the reporting periods presented herein.

8

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

Inventory

Inventory consisting of supplements, is stated at the lower of cost or net realizable value. Cost is determined by the first-in, first-out method. Outdated inventory is directly charged to cost of goods sold.

Intangible Assets

The Company recognizes an acquired intangible whenever the intangible arises from contractual or other legal rights, or whenever it can be separated or divided from the acquired entity and sold, transferred, licensed, rented or exchanged, either individually or in combination with a related contract, asset or liability. Such intangibles are amortized over their estimated useful lives unless the estimated useful life is determined to be indefinite. Amortizable intangible assets are being amortized primarily over useful lives of five years. The straight-line method of amortization is used as it has been determined to approximate the use pattern of the assets. Impairment losses are recognized if the carrying amount of an intangible that is subject to amortization is not recoverable from expected future cash flows and its carrying amount exceeds its fair value.

Concentrations of Credit Risk

The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. There are no patients/customers that represent 10% or more of the Company’s revenue or accounts receivable. Generally, the Company’s cash and cash equivalents are in checking accounts. The Company relies on a sole supplier for the fulfillment of substantially all of its product sales made through MOD.

Property and Equipment

Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For consolidated financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 to 7 years. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized.

The Company examines the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.

Fair Value of Assets and Liabilities

Fair value is the price that would be received from the sale of an asset or paid to transfer a liability (i.e. an exit price) in the principal or most advantageous market in an orderly transaction between market participants. In determining fair value, the accounting standards have established a three-level hierarchy that distinguishes between (i) market data obtained or developed from independent sources (i.e., observable data inputs) and (ii) a reporting entity’s own data and assumptions that market participants would use in pricing an asset or liability (i.e., unobservable data inputs). Financial assets and financial liabilities measured and reported at fair value are classified in one of the following categories, in order of priority of observability and objectivity of pricing inputs:

|  |  |  |
| --- | --- | --- |
|  | ● | Level 1 – Fair value based on quoted prices in active markets for identical assets or liabilities; |

|  |  |  |
| --- | --- | --- |
|  | ● | Level 2 – Fair value based on significant directly observable data (other than Level 1 quoted prices) or significant indirectly observable data through corroboration with observable market data. Inputs would normally be (i) quoted prices in active markets for similar assets or liabilities, (ii) quoted prices in inactive markets for identical or similar assets or liabilities or (iii) information derived from or corroborated by observable market data; |

|  |  |  |
| --- | --- | --- |
|  | ● | Level 3 – Fair value based on prices or valuation techniques that require significant unobservable data inputs. Inputs would normally be a reporting entity’s own data and judgments about assumptions that market participants would use in pricing the asset or liability. |

9

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

The fair value measurement level for an asset or liability is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques should maximize the use of observable inputs and minimize the use of unobservable inputs.

The Company utilizes a binomial lattice option pricing model to estimate the fair value of options, warrants, beneficial conversion features and other Level 3 financial assets and liabilities. The Company believes that the binomial lattice model results in the best estimate of fair value because it embodies all of the requisite assumptions (including the underlying price, exercise price, term, volatility, and risk-free interest-rate) necessary to fairly value these instruments and, unlike less sophisticated models like the Black-Scholes model, it also accommodates assumptions regarding investor exercise behavior and other market conditions that market participants would likely consider in negotiating the transfer of such an instruments.

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and nonemployees under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718 “Compensation – Stock Compensation” using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity’s equity instruments or that may be settled by the issuance of those equity instruments. The Company uses a binomial lattice pricing model to estimate the fair value of options and warrants granted.

Income Taxes

The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. No income tax has been provided for the three months ended March 31, 2024 since the Company sustained a loss in that period. No income tax was provided for the three months ended March 31, 2023 because the Company had sufficient operating loss carryforwards to offset any net income for the full year 2023, including income from capital gains related to the disposal of discontinued operations. The Company recognized net loss for the full year 2023. Due to the uncertainty of the utilization and recoverability of the loss carry-forwards and other deferred tax assets, management has determined a full valuation allowance for the deferred tax assets, since it is more likely than not that the deferred tax assets will not be realizable.

Recurring Fair Value Measurements

The carrying value of the Company’s financial assets and financial liabilities is their cost, which may differ from fair value. The carrying value of cash held as demand deposits, money market and certificates of deposit, marketable investments, accounts receivable, accounts payable, and accrued liabilities approximated their fair value.

10

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

Net Income (Loss) per Share

Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. During the three months ended March 31, 2024 and 2023, the Company reported a loss from continuing operations. As a result, diluted net income (loss) per common share is computed in the same manner as basic net income (loss) per common share, even though the Company had net income in the three months ended March 31, 2023 after adjusting for discontinued operations. The Company excluded all outstanding stock options, warrants and other dilutive securities from the calculation of diluted net loss per common share because inclusion of these securities would have been anti-dilutive. As of March 31, 2024 and December 31, 2023, potentially dilutive securities were comprised of (i) 85,357,246 and 77,414,648 warrants outstanding, respectively, (ii) 7,063,146 and 5,093,738 stock options outstanding, respectively, (iii) 1,026,324 and 1,484,488 unissued shares subject to future vesting requirements granted pursuant to the Company’s Employee Incentive Plan, (iv) up to 1,055,536 and 2,764,352 common shares issuable that are earned but not paid under consulting and director compensation arrangements, and (v) up to 13,750,000 and 13,750,000 shares of common stock issuable upon conversion of Series B Preferred.

Common Stock Awards

The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded on the consolidated statement of operations in the same manner and charged to the same account as if such settlements had been made in cash. From time to time, the Company also issues stock awards settleable in a variable number of common shares. Such awards are classified as liabilities until such time as the number of shares underlying the grant is determinable.

Warrants

In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes pricing model as of the measurement date. The Company uses a binomial lattice pricing model to estimate the fair value of compensation options and warrants. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period, or at the date of issuance, if there is not a service period. Certain of the Company’s warrants include a so-called down round provision. The Company accounts for such provisions pursuant to ASU No. 2017-11, *Earnings Per Share, Distinguishing Liabilities from Equity and Derivatives and Hedging*, which calls for the recognition of a deemed dividend in the amount of the incremental fair value of the warrant due to the down round when triggered.

Business Segments

The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has three operating segments: Health Services (multi-specialty medical group including the NWC GYN practice, the NCFM functional medicine practice, the BTG physical therapy practice, and the AEU cosmetic services practice), Digital Healthcare (develops and markets the “HealthLynked Network,” an online personal medical information and record archive system), and Medical Distribution (comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices).

The Company’s ACO/MSO segment was sold on January 17, 2023. As described in further detail in Note 4, “Discontinued Operations,” this unit’s assets and liabilities are classified as held for sale as of December 31, 2022 and the unit’s results of operations are classified as “Income (loss) from operations of discontinued operations” in the three months ended March 31, 2024 and 2023.

11

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

Recently Adopted Pronouncements

In March 2020, the FASB issued ASU 2020-03, “Codification Improvements to Financial Instruments.” The amendments in this update are to clarify, correct errors in, or make minor improvements to a variety of ASC topics. The changes in ASU 2020-03 are not expected to have a significant effect on current accounting practices. The ASU improves various financial instrument topics in the Codification to increase stakeholder awareness of the amendments and to expedite the improvement process by making the Codification easier to understand and easier to apply by eliminating inconsistencies and providing clarifications. The ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022 with early application permitted. The Company adopted this standard for the year ended December 31, 2023. The adoption did not have a material effect on the Company’s consolidated financial statements.

In October 2021, the FASB issued guidance which requires companies to apply Topic 606, *Revenue from Contracts with Customers*, to recognize and measure contract assets and contract liabilities from contracts with customers acquired in a business combination. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2022 and interim periods within those fiscal years, with early adoption permitted. The Company adopted this standard for the year ended December 31, 2023. The adoption did not have a material effect on the Company’s consolidated financial statements.

In November 2023, the FASB issued Accounting Standards Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the three months ended March 31, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements.

In December 2023, the FASB issued Accounting Standards Update 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted this standard in the three months ended March 31, 2024. The adoption did not have a material effect on the Company’s consolidated financial statements.

No other new accounting pronouncements were issued or became effective in the period that had, or are expected to have, a material impact on our consolidated Financial Statements.

**NOTE 3 – LIQUIDITY AND GOING CONCERN ANALYSIS**

Under ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. Pursuant to ASU 2014-15, in evaluating the Company’s ability to continue as a going concern, management considered the conditions and events that could raise substantial doubt about the Company’s ability to continue as a going concern within 12 months after the Company’s financial statements were issued (May 15, 2025). Management considered the Company’s current financial condition and liquidity sources, including current funds available, forecasted future cash flows and the Company’s obligations due before May 15, 2025.

The Company is subject to a number of risks, including uncertainty related to product development and generation of revenues and positive cash flow from its Digital Healthcare Division and a dependence on outside sources of capital. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill the Company’s growth and operating activities and generating a level of revenues adequate to support the Company’s cost structure.

As of March 31, 2024, the Company had cash balances of $23,491, a working capital deficit of $798,224 and an accumulated deficit of $43,420,854. For the three months ended March 31, 2024, the Company had a net loss of $1,387,718 and used cash from operating activities of $854,855. The Company expects to continue to incur net losses and have significant cash outflows for at least the next 12 months.

12

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 3 – LIQUIDITY AND GOING CONCERN ANALYSIS (CONTINUED)**

Management has evaluated the significance of the conditions described above in relation to the Company’s ability to meet its obligations and concluded that, without additional funding, the Company will not have sufficient funds to meet its obligations within one year from the date the consolidated financial statements were issued.

As described further in Note 4, “Discontinued Operations,” on January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and the Company agreed to sell, AHP. The Company received $750,000 upon signing of the AHP Merger Agreement, the $31,381 Stub Period Reimbursement (defined below) in March 2023, $1,750,000 ($1,540,000 net after commissions) during June, July and August 2023 for meeting 100% of the participating physician transfer milestones outlined in the AHP Merger Agreement, and $1,873,993 ($1,186,231 net after commissions and other expenses) related to AHP’s Plan Year 2022 MSSP shared savings. The Company may also receive future proceeds under the AHP Merger Agreement comprised of (i) up to $500,000 from the Buyer’s plan year 2023 (and if necessary, 2024) MSSP Shared Savings to reimburse amounts advanced to participating physicians at signing that would be received in October 2024, and (ii) proceeds from sale of shares of the Buyer’s common stock if the Buyer completes an initial public offering by February 1, 2025.

During the three months ended March 31, 2024, the Company also (i) received net proceeds from the issuance of notes payable to related parties and third parties totaling $500,000 and made repayments on existing and new notes payable to related parties and third parties totaling $221,278, and (ii) received $355,000 proceeds from the sale of its common stock.

On July 5, 2022, the Company entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”) (See Note 13, “Shareholders’ Equity,” below for additional information on the SEPA). Pursuant to the SEPA, the Company shall have the right to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the three-year commitment period set forth in the SEPA. Because the purchase price per share to be paid by Yorkville for the shares of common stock sold by the Company to Yorkville pursuant to the SEPA, if any, will fluctuate based on the market prices of the Company’s common stock during the applicable pricing period, the Company cannot reliably predict the actual purchase price per share to be paid by Yorkville for those shares, or the actual gross proceeds to be raised by the Company from those sales, if any. During the three months ended March 31, 2023, the Company sold 225,000 shares of common stock under the SEPA, receiving $18,765 in proceeds, all of which was applied to the balance of a then-outstanding promissory note payable to Yorkville. The Company has not made any draws pursuant to the SEPA since January 2023.

Without raising additional capital, either via additional advances made pursuant to the SEPA or from other sources, there is substantial doubt about the Company’s ability to continue as a going concern through May 15, 2025. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of presentation contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

13

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 4 – DISCONTINUED OPERATIONS**

Description of Transaction

During the fourth quarter of 2022, the Board approved a plan to sell the Company’s ACO/MSO Division, which assists physician practices in providing coordinated and more efficient care to patients via the MSSP as administered by the CMS, which rewards providers for efficiency in patient care. On January 17, 2023, the Company entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and the Company agreed to sell, AHP (the “AHP Sale”). Pursuant to the terms of the AHP Merger Agreement, the Company received or will receive the following consideration: (1) $750,000 in cash paid upon signing of the definitive agreement (received January 18, 2023) (the “Upfront Cash Consideration”); (2) the Buyer shall reimburse the Company for expenses incurred by the Company in operating AHP from January 1, 2023 to January 16, 2023 (the “Stub Period Reimbursement”)($31,381 paid in March 2023); (3) up to $1,750,000 net incremental cash based on the agreement to participate in Buyer’s ACO by AHP’s existing physician practices or newly added practices, scaled based on the number of covered patients transferred to PBACO by July 31, 2023 (the “Incremental Cash Consideration”), of which $1,225,000 ($1,180,000 net after commissions) was received in June 2023 and $150,000 ($120,000 net after commissions) was received in July 2023; (4) net proceeds, including allocation for expenses, from any MSSP Shared Savings related to AHP’s plan year 2022 (the “2022 MSSP Consideration”), of which the Company realized gross receipts of $1,873,993 and net proceeds of $1,186,231 after payments to participating physicians and commissions in October 2023; (5) $500,000 of the Incremental Cash Consideration will be allocated to AHP’s participating physicians upon receipt and will be reimbursed to HealthLynked by the Buyer in 2024 from the Buyer’s plan year 2023 (and if necessary, 2024) MSSP Shared Savings (the “Physician Advance Consideration”); and (6) in the event that Buyer completes a planned initial public offering (“IPO”) by February 1, 2025, shares in the public entity at the time of the IPO with a value equal to AHP’s 2021 earnings before interest, taxes depreciation and amortization (“EBITDA”) times the multiple of EBITDA used to value the public entity’s IPO shares, net of any cash consideration previously paid by the Buyer and subject to vesting requirements detailed in the AHP Merger Agreement (the “IPO Share Consideration”). The Company is also required to indemnify the Buyer against liabilities arising from Buyer’s operation of AHP prior to the Buyer’s IPO date, less a deductible equal to 1% of the aggregate merger consideration (the “Indemnification Clause”).

In the event Buyer goes public through means other than an IPO, the parties agreed to modify the terms of the IPO Share Consideration to implement such alternate structure. In the event Buyer does not go public by IPO or other means by February 1, 2025, the Company receives no IPO Share Consideration, and the Transaction consideration is capped at the cash consideration of up to $3,000,000 plus the MSSP Consideration. Any participating physician advances will be repaid to the Company out of AHP’s 2023 performance year MSSP Shared Savings, which would be received in 2024.

Pursuant to the terms of the Merger Agreement, formal transfer of the equity ownership of AHP from the Company to the Buyer will occur at the earlier of (i) Buyer’s IPO, (ii) Buyer going public by other means, or (iii) if Buyer does not go public, on February 1, 2025. Until that time, the Company has the right, but not the obligation, to reacquire AHP for a price equal to any consideration already paid by the Buyer for AHP, plus all expenses incurred by Buyer in operating AHP after January 16, 2023.

Concurrent with the AHP Merger Agreement, AHP and the Buyer also entered into a Management Services Agreement (the “MSA”), pursuant to which the Buyer assumed full control of managing AHP’s business operations and paying AHP’s operating expenses after January 16, 2023. The term of the MSA is from January 17, 2023 to August 1, 2024, which is the latest date that equity ownership of AHP can transfer from the Company to the Buyer. The Buyer agreed in the Merger Agreement to reimburse the Company for reasonable expenses incurred by the Company in operating AHP from January 1, 2023 to January 16, 2023, which we refer to as the Stub Period Reimbursement, during which time the Company had operational and financial control of AHP and CHM. Concurrent with the AHP Merger Agreement and the MSA, and as a result of the Buyer assuming control and responsibility of AHP’s operations, the Company discontinued its operations of CHM.

Discontinued Operations

The Company has classified the results of the ACO/MSO Division as discontinued operations in the accompanying consolidated statement of operations for all periods presented. No assets or liabilities were classified as held for sale as of March 31, 2024 or December 31, 2023.

14

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 4 – DISCONTINUED OPERATIONS (CONTINUED)**

The financial results of the ACO/MSO Division are presented as income (loss) from discontinued operations, net of income taxes on our consolidated statement of operations. The following table presents financial results of the ACO/MSO Division for the three months ended March 31, 2024:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| **Revenue:** |  |  | |  |  |  | |  |
| Consulting revenue |  | $ | --- |  |  | $ | 23,646 |  |
| Total revenue |  |  | --- |  |  |  | 23,646 |  |
|  |  |  |  |  |  |  |  |  |
| **Operating Expenses and Costs:** |  |  |  |  |  |  |  |  |
| Medicare shared savings expenses |  |  | --- |  |  |  | 67,935 |  |
|  |  |  |  |  |  |  |  |  |
| Loss from operations of discontinued operations before income taxes |  |  | --- |  |  |  | (44,289 | ) |
| Provision for income taxes |  |  | --- |  |  |  | --- |  |
|  |  |  |  |  |  |  |  |  |
| Loss from discontinued operations, net of income taxes |  | $ | --- |  |  | $ | (44,289 | ) |

Net cash used in operations of the ACO/MSO Division was $-0- and $47,163 in the three months ended March 31, 2024 and 2023, respectively. There were no cash flows from investing or financing activities of the ACO/MSO Division in the three months ended March 31, 2024 and 2023.

Derecognition and Gain from Disposal of Discontinued Operations

As a result of the AHP Sale and pursuant to the terms and conditions of the AHP Merger Agreement and the MSA, the Company ceased to have a controlling financial interest in AHP as of January 17, 2023. Accordingly, in connection with the transaction, the Company deconsolidated AHP as of January 17, 2023.

In connection with the deconsolidation, the Company recognized the fair value of consideration received and receivable from the AHP Sale, recognized an indemnification liability related to potential claims resulting from the AHP Sale, derecognized the carrying value of assets and liabilities transferred to the Buyer or otherwise derecognized in connection with in the AHP Sale, and recorded a gain on sale for the excess of consideration received over carrying value of assets derecognized and liabilities recognized.

The Company elected to record the contingent portion of consideration receivable at fair value on the sale date pursuant to the guidance in FASB Emerging Issues Task Force Issue 09-4, “Seller Accounting for Contingent Consideration,” (“EITF 09-4”). The fair value of consideration received and receivable is shown in the following table:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Upfront Cash Consideration paid at signing |  | $ | 750,000 |  |
|  |  |  |  |  |
| Incremental Cash Consideration |  |  | 1,311,567 |  |
| IPO Share Consideration |  |  | 1,463,517 |  |
| 2022 MSSP Consideration |  |  | 312,987 |  |
| Physician Advance Consideration |  |  | 199,645 |  |
| Stub Period Reimbursement |  |  | 31,381 |  |
| Total fair value of contingent consideration receivable |  |  | 3,319,097 |  |
|  |  |  |  |  |
| Total fair value of consideration received and receivable |  | $ | 4,069,097 |  |

15

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 4 – DISCONTINUED OPERATIONS (CONTINUED)**

The fair value of contingent consideration receivable was determined using an expected present value approach, which applies a discount rate to a probability-weighted stream of net cash flows based on multiple scenarios, as estimated by management. As such, the fair values of contingent consideration receivable rely on significant unobservable inputs and assumptions and there is uncertainty in the expected future cash flows used in the fair valuation. Significant assumptions related to the valuation of contingent consideration receivable include the likelihood of a Buyer IPO, the valuation of the Buyer’s common stock in a potential IPO, the likelihood that AHP would meet its performance benchmarks to the extent that it will receive shared savings for plan year 2022, the likelihood that AHP under the management of the Buyer would receive sufficient shared savings in plan years 2023 and/or 2024 to pay the Physician Advance Consideration, and the likelihood that the Company would be able to transfer or add new participating physicians to AHP before July 31, 2023 in order to collect the Incremental Cash Consideration.

The book value of the assets and liabilities derecognized on January 17, 2023 in connection with the sale were as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Prepaid expenses |  | $ | 1,500 |  |
| Intangible asset - ACO physician contract |  |  | 1,073,000 |  |
| Goodwill |  |  | 381,856 |  |
| Contract liability |  |  | (20,278 | ) |
| Contingent acquisition consideration |  |  | (185,024 | ) |
| Net Book Value of Assets and Liabilities Sold |  | $ | 1,251,054 |  |

Prepaid expenses are prepaid services from which the Buyer will benefit following the AHP Sale. Intangible assets and goodwill represent the carrying value of assets recorded at the time the Company acquired CHM and AHP in 2020 (the “Original Acquisition”). Contract liability represents remaining unearned revenue for which the Buyer is required to provide the performance obligations after January 17, 2023. In connection with the AHP Sale, the remaining value of contingent acquisition consideration (“CAC”) related to the Original Acquisition was written off.

After recording the fair value of consideration and derecognition of assets and liabilities, and an estimated liability related to the Indemnification Clause, the Company recorded a gain from disposal of discontinued operations in the amount of $2,674,069 in the three months ended Mach 31, 2023 as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Total fair value of consideration received and receivable |  | $ | 4,069,097 |  |
| Less: net book value of assets and liabilities sold |  |  | (1,251,054 | ) |
| Less: fair value of Indemnification Clause |  |  | (143,974 | ) |
|  |  |  |  |  |
| Gain from disposal of discontinued operations |  | $ | 2,674,069 |  |

After January 17, 2023, and as prescribed under EITF 09-4, the Company has elected to subsequently treat the contingent consideration receivable using gain contingency guidance and only record a gain or loss when the contingency is resolved. Accordingly, the Company does not prospectively remeasure the fair value of contingent consideration receivable each reporting period.

Receipts of Contingent Sale Consideration Receivable

The Company received $750,000 upon signing of the AHP Merger Agreement, the $31,381 Stub Period Reimbursement in March 2023, $1,750,000 ($1,540,000 net after commissions) Incremental Cash Consideration during June, July and August 2023 for meeting 100% of the participating physician transfer milestones outlined in the AHP Merger Agreement, and $1,873,993 ($1,186,231 net after commissions and other expenses) in October 2023 related to AHP’s Plan Year 2022 MSSP shared savings.

The carrying value of the remaining unresolved components of contingent consideration receivable as of March 31, 2024 and December 31, 2023 was as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| IPO Share Consideration |  | $ | 1,463,518 |  |
| Physician Advance Consideration |  |  | 199,645 |  |
| Remaining contingent sale consideration receivable |  | $ | 1,663,163 |  |

16

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 5 – PREPAID EXPENSES AND OTHER**

Prepaid and other expenses as of March 31, 2024 and December 31, 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Insurance prepayments |  | $ | 7,791 |  |  | $ | 11,209 |  |
| Other expense prepayments |  |  | 22,475 |  |  |  | 38,391 |  |
| Rent deposits |  |  | 50,047 |  |  |  | 50,547 |  |
| Contract assets |  |  | 9,750 |  |  |  | 5,110 |  |
| Total prepaid expenses and other |  |  | 90,063 |  |  |  | 105,257 |  |
| Less: long term portion |  |  | (50,047 | ) |  |  | (50,047 | ) |
| Prepaid expenses and other, current portion |  | $ | 40,016 |  |  | $ | 55,210 |  |

Contract assets relate to amounts incurred to obtain a customer contract that would not have been incurred if the contract had not been obtained, such as commissions, associated with NCFM annual access contracts.

**NOTE 6 – PROPERTY AND EQUIPMENT**

Property and equipment as of March 31, 2024 and December 31, 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Medical equipment |  | $ | 496,452 |  |  | $ | 493,854 |  |
| Furniture, office equipment and leasehold improvements |  |  | 317,963 |  |  |  | 317,963 |  |
|  |  |  |  |  |  |  |  |  |
| Total property and equipment |  |  | 814,415 |  |  |  | 811,817 |  |
| Less: accumulated depreciation |  |  | (550,531 | ) |  |  | (521,062 | ) |
|  |  |  |  |  |  |  |  |  |
| Property and equipment, net |  | $ | 263,884 |  |  | $ | 290,755 |  |

Depreciation expense during the three months ended March 31, 2024 and 2023 was $29,469 and $31,037, respectively.

**NOTE 7 – INTANGIBLE ASSETS**

Identifiable intangible assets as of March 31, 2024 and December 31, 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| NCFM: Medical database |  | $ | 1,101,538 |  |  | $ | 1,101,538 |  |
| NCFM: Website |  |  | 41,000 |  |  |  | 41,000 |  |
|  |  |  |  |  |  |  |  |  |
| Total intangible assets |  |  | 1,142,538 |  |  |  | 1,142,538 |  |
| Less: accumulated amortization |  |  | (315,730 | ) |  |  | (258,690 | ) |
|  |  |  |  |  |  |  |  |  |
| Intangible assets, net |  | $ | 826,808 |  |  | $ | 883,848 |  |

17

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 7 – INTANGIBLE ASSETS (CONTINUED)**

Intangible assets arose from the acquisition of NCFM in April 2019. The NCFM medical database is being prospectively amortized starting January 1, 2023 over an estimated five-year useful life. The NCFM website began being amortized over a five-year life from the acquisition date. Amortization expense related to intangible assets in the three months ended March 31, 2024 and 2023 was $57,040 and $57,040, respectively.

Future amortization expense of intangible assets is expected to be as follows:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 2024 (April to December) |  | $ | 165,885 |  |
| 2025 |  |  | 220,308 |  |
| 2026 |  |  | 220,308 |  |
| 2027 |  |  | 220,307 |  |
| Thereafter |  |  | --- |  |
|  |  |  |  |  |
| Total future amortization expense |  | $ | 826,808 |  |

**NOTE 8 – LEASES**

The Company has separate operating leases, and related amendments thereto, for office space related to its NWC, NCFM, BTG and AEU practices, its corporate headquarters, and a copier lease that expire in July 2026, May 2025, March 2024, March 2026, November 2026, and January 2027, respectively. As of March 31, 2024, the Company’s weighted-average remaining lease term relating to its operating leases was 2.4 years, with a weighted-average discount rate of 15.44%.

The table below summarizes the Company’s lease-related assets and liabilities as of March 31, 2024 and December 31, 2023:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| Lease assets |  | $ | 853,525 |  |  | $ | 935,812 |  |
|  |  |  |  |  |  |  |  |  |
| **Lease liabilities** |  |  |  |  |  |  |  |  |
| Lease liabilities (short term) |  | $ | 332,692 |  |  | $ | 326,033 |  |
| Lease liabilities (long term) |  |  | 524,546 |  |  |  | 613,386 |  |
| Total lease liabilities |  | $ | 857,238 |  |  | $ | 939,419 |  |

Lease expense was $129,431 and $111,905 in the three months ended March 31, 2024 and 2023, respectively.

Maturities of operating lease liabilities were as follows as of March 31, 2024:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 2024 |  | $ | 390,027 |  |
| 2025 |  |  | 467,994 |  |
| 2026 |  |  | 335,634 |  |
| 2027 |  |  | 990 |  |
| Total lease payments |  |  | 1,194,645 |  |
| Less interest |  |  | (337,407 | ) |
| Present value of lease liabilities |  | $ | 857,238 |  |

18

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 9 – ACCOUNTS PAYABLE, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES**

Amounts related to accounts payable, accrued expenses and other current liabilities as of March 31, 2024 and December 31, 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Trade accounts payable |  | $ | 372,612 |  |  | $ | 251,479 |  |
| Accrued payroll liabilities |  |  | 76,646 |  |  |  | 110,103 |  |
| Accrued operating expenses |  |  | 175,349 |  |  |  | 91,238 |  |
| Accrued interest |  |  | 52,287 |  |  |  | 57,074 |  |
| Accrued commissions payable from 2022 MSSP Consideration (a) |  |  | 25,000 |  |  |  | 100,000 |  |
| Contingent acquisition consideration payable (b) |  |  | 2,113 |  |  |  | 2,189 |  |
| Product return allowance |  |  | 1,117 |  |  |  | 2,095 |  |
|  |  | $ | 705,124 |  |  | $ | 614,178 |  |

|  |  |
| --- | --- |
| (a) | During September 2023, AHP received from the CMS a final determination of AHP’s Plan Year 2022 MSSP shared savings, of which the Company realized gross receipts of $1,873,993 and net proceeds of $1,186,231 after payments to participating physicians and commissions in satisfaction of the 2022 MSSP Consideration. Gross payment was received by the Company in October 2023. As of December 31, 2023, the Company’s remaining accrued commissions and other fees payable resulting from the receipt and prior consideration received in the amount of $100,000, of which $75,000 was paid in the three months ended March 31, 2024. See Note 4 for complete description of the AHP Sale and related consideration. |
| (b) | Contingent acquisition consideration reflects the fair value of the final earn-out payment potentially payable related to the Company’s acquisitions of MOD in 2020.  All of the remaining $2,113 contingent acquisition consideration related to MOD matures in 2024 based on the performance of the business unit for the year ended December 31, 2024. |

**NOTE 10 – CONTRACT LIABILITIES**

Amounts related to contract liabilities as of March 31, 2024 and December 31, 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Patient services paid but not provided - NCFM |  | $ | 175,333 |  |  | $ | 95,334 |  |
| Patient services paid but not provided - BTG |  |  | 90,599 |  |  |  | 100,857 |  |
| Patient services paid but not provided - NWC |  |  | 64,114 |  |  |  | 75,438 |  |
| Unshipped products - MOD |  |  | 1,394 |  |  |  | 145 |  |
|  |  | $ | 331,440 |  |  | $ | 271,774 |  |

Contract liabilities relate to (i) NCFM annual access contracts, including Medical Membership, Concierge Service and Optimal Health 365 Access Plan contracts pursuant to which patients prepay for access to services to be provided at the patient’s request over a period of time, (ii) BTG contracts pursuant to which patients prepay for access to a fixed number of visits used at the patients’ discretion, (iii) NWC annual administration fees, and (iv) MOD sold but unshipped products.

19

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS**

Amounts due to related parties as of March 31, 2024 and December 31, 2023 were comprised of the following:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| Note Payable to Dr. Michael Dent, March 2023 |  | $ | --- |  |  | $ | 12,601 |  |
| Note Payable to Dr. Michael Dent, June 2023 |  |  | --- |  |  |  | 26,875 |  |
| Note Payable to Dr. Michael Dent, December 2023 |  |  | --- |  |  |  | 166,500 |  |
| Convertible Note Payable I to Dr. Michael Dent, March 2024 |  |  | 150,000 |  |  |  | --- |  |
| Convertible Note Payable II to Dr. Michael Dent, March 2024 |  |  | 350,000 |  |  |  | --- |  |
| Convertible Note Payable III to Dr. Michael Dent, March 2024 |  |  | 199,621 |  |  |  | --- |  |
| Face value of notes payable to related party |  |  | 699,621 |  |  |  | 205,976 |  |
| Less: unamortized discounts |  |  | (281,579 | ) |  |  | (34,834 | ) |
| Notes payable to related party, total |  |  | 418,042 |  |  |  | 171,142 |  |
| Plus deferred compensation payable to Dr. Michael Dent |  |  | 300,600 |  |  |  | 300,600 |  |
| Total due to related party |  | $ | 718,642 |  |  | $ | 471,742 |  |

Notes Payable to Dr. Michael Dent

On November 8, 2022, the Company entered into a Merchant Cash Advance Factoring Agreement with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of $150,000 (the “November MCA”). The Company was required to repay the November MCA at the rate of $3,750 per week until the balance of $195,000 was repaid, which was scheduled for November 2023. At inception, the Company recognized a note payable in the amount of $195,000 and a discount against the note payable of $45,000. The discount was being amortized over the life of the November MCA. The Company made payments totaling $-0- and $33,750 in the three months ended March 31, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $11,219 in the three months ended March 31, 2024 and 2023, respectively. The November MCA was repaid in full during the fourth quarter of 2023. As of March 31, 2024 and December 31, 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On December 13, 2022, the Company entered into a Merchant Cash Advance Factoring Agreement with a trust controlled by Dr. Dent, pursuant to which the Company received an advance of $110,000 (the “December MCA”). The Company was required to repay the December MCA at the rate of $2,750 per week until the balance of $143,000 was repaid, which was scheduled for December 2023. In connection with the December MCA, the Company issued 3,142,857 three-year warrants to the holder with an exercise price of $0.035. The fair value of the warrants was $63,420. At inception, the Company recognized a note payable in the amount of $143,000 and a discount against the note payable of $68,281 for the allocated fair value of the original issue discounts and warrants. The discount was being amortized over the life of the December MCA. The Company made payments totaling $-0- and $24,750 in the three months ended March 31, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $17,070 in the three months ended March 31, 2024 and 2023, respectively. The December MCA was repaid in full during the fourth quarter of 2023. As of March 31, 2024 and December 31, 2023, remaining payments were $-0- and $-0-, respectively, and the net carrying value was $-0- and $-0-, respectively.

On January 5, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $10,000 (the “$10k Dent Note”). The $10k Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the $10k Dent Note, the Company issued 96,154 five-year warrants to the holder with an exercise price of $0.104. The fair value of the warrants was $6,843. At inception, the Company recognized a note payable in the amount of $10,000 and a discount against the note payable of $3,851 for the allocated fair value of the warrants. The discount was to be amortized over the life of the $10k Dent Note. The $10k Dent Note was repaid in full during January 2023. Amortization of debt discount and interest expense prior to repayment were $269 and $53, respectively, in the three months ended March 31, 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $3,582 in the three months ended March 31, 2023.

20

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

On January 13, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $161,000 (the “January 2023 Dent Note”). Net proceeds were $160,000, taking into account the original issue discount of $1,000. The January 2023 Dent Note bore interest at a rate of 15% per annum and was scheduled to mature six months from issuance. In connection with the January 2023 Dent Note, the Company issued 860,215 three-year warrants to Dr. Dent with an exercise price of $0.093. The fair value of the warrants was $56,123. At inception, the Company recognized a note payable in the amount of $161,000 and a discount against the note payable of $42,553 for the allocated fair value of the original issue discount and warrants. The discount was to be amortized over the life of the January 2023 Dent Note. The January 2023 Dent Note was repaid in full during January 2023. Amortization of debt discount and interest expense prior to repayment were $1,373 and $397, respectively, in the three months ended March 31, 2023. In connection with the repayment, the Company recognized a loss on extinguishment of debt of $41,181 in the three months ended March 31, 2023.

On February 14, 2023, the Company issued an unsecured promissory note to Dr. Dent with a face value of $186,000 (the “February 2023 Dent Note”). Net proceeds were $185,000 after an original issue discount of $1,000. The February 2023 Dent Note bore interest at a rate of 15% per annum and matured six months from issuance. In connection with the February 2023 Dent Note, the Company issued 685,185 three-year warrants to Dr. Dent with an exercise price of $0.135. The fair value of the warrants was $66,136. At inception, the Company recognized a note payable in the amount of $186,000 and a discount against the note payable of $50,989 for the allocated fair value of the original issue discounts and warrants. The discount was amortized over the life of the February 2023 Dent Note. No payments were made on the February 2023 Dent Note in the three months ended March 31, 2023. Amortization of debt discount and interest expense were $1,373 and $3,440, respectively, in the three months ended March 31, 2023.

On March 14, 2023, the Company issued a promissory note payable to a trust controlled by Dr. Dent with a stated principal amount of $112,510 and prepaid interest of $13,501 for total scheduled repayments of $126,011 (the “March 2023 Dent Note”). The March 2023 Dent Note had an original issue discount of $12,510, resulting in net proceeds to the Company of $100,000. At inception, the Company recognized a note payable in the amount of $126,011 and a discount against the note payable of $26,011. The March 2023 Dent Note did not bear interest in excess of the prepaid interest and original issue discount and matured on March 14, 2024. The Company was required to make 10 monthly payments of $12,601 starting April 30, 2023. At inception, the Company recorded a discount against the note of $26,011, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. The March 2023 Dent Note gave the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. The Company made payments totaling $12,601 and $-0- in the three months ended March 31, 2024 and 2023, respectively. Amortization of debt discount was $2,504 and $1,292 in the three months ended March 31, 2024 and 2023, respectively. The March 2023 Dent Note was repaid in January 2024.

On June 26, 2023, the Company issued an unsecured promissory note to Dr. Michael Dent with a face value of $25,000 (the “June 2023 Dent Note”). The June 2023 Dent Note bore a fixed interest charge of $1,875 (15% per annum) and matured on December 26, 2023. At inception, the Company recorded a note payable in the amount of $26,875 and a discount against the note of $1,875. The Company made payments totaling $25,000 and $-0- in the three months ended March 31, 2024 and 2023, respectively. Amortization of debt discount was $-0- and $1,292 in the three months ended March 31, 2024 and 2023, respectively. The June 2023 Dent Note was repaid in January 2024.

On December 1, 2023, the Company issued an unsecured promissory note to a trust controlled by Dr. Dent with a face value of $150,000 (the “December 2023 Dent Note”). The December 2023 Dent Note bore a fixed interest charge of $15,000 (10% per annum) and $1,500 in fixed fees and matured on February 28, 2024. The Company received net proceeds of $150,000 after discounts and fees. In connection with the note, the Company issued 1,500,000 five-year warrants to the holder with an exercise price of $0.06. The fair value of the warrants was $32,269. At inception, the Company recorded a note payable in the amount of $166,500 and a discount against the note payable of $48,769 for the allocated fair value of the original issue discount and warrants. The Company made payments totaling $-0- and $-0- in the three months ended March 31, 2024 and 2023, respectively, on the December 2023 Dent Note. Amortization of debt discount was $32,330 and $-0- in the three months ended March 31, 2024 and 2023, respectively. On March 27, 2024, the December 2023 Dent Note was refinanced and replaced with the March 2024 Dent Note III as described below. No loss on extinguishment of debt was recognized in the three months ended March 31, 2024 because the discount was fully amortized at the time of the refinancing.

21

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 11 – AMOUNTS DUE TO RELATED PARTY AND RELATED PARTY TRANSACTIONS (CONTINUED)**

On March 27, 2024, the Company issued to a trust controlled by Dr. Michael Dent three separate notes payable as follows: (1) a note payable with a principal of $350,000, an interest rate of 12% per annum, and a maturity date of June 27, 2024 (the “March 2024 Dent Note I”), (2) a note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of August 24, 2024 (the “March 2024 Dent Note II”), and (3) a note payable with a principal of $166,500, an interest rate of 12% per annum, and a maturity date of August 28, 2024 (the “March 2024 Dent Note III”, and collectively, the “March 2024 Dent Notes”). The full amount of principal and accrued interest on each of the March 2024 Dent Notes is due at the respective maturity date of each note. Each of the March 2024 Dent Notes is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.0573 per share. In connection with the issuance of the March 2024 Dent Notes, the Company also issued to the holder a ten-year warrant to purchase 6,660,000 shares of the Company’s common stock at an exercise price of $0.06 per share (the “March 2024 Warrant”). The fair value of the March 2024 Warrant was $254,345.

Net proceeds from the March 2024 Dent Note I were $350,000. At inception, the Company recorded a discount of $203,588, representing the allocated fair value of the beneficial conversion feature (“BCF”) and the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note I. The discount is being amortized over the life of the note. Amortization expense related to the note discount was $8,852 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made no payments against the March 2024 Dent Note I in the three months ended March 31, 2024 or 2023. As of March 31, 2024 and December 31, 2023, remaining principal payments were $350,000 and $-0-, respectively, the net carrying value was $155,264 and $-0-, respectively, and accrued interest was $460 and $-0-, respectively.

Net proceeds from the March 2024 Dent Note II were $150,000. At inception, the Company recorded a discount of $89,222, representing the allocated fair value of the BCF and the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note II. The discount is being amortized over the life of the note. Amortization expense related to the note discount was $2,379 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made no payments against the March 2024 Dent Note II in the three months ended March 31, 2024 or 2023. As of March 31, 2024 and December 31, 2023, remaining principal payments were $150,000 and $-0-, respectively, the net carrying value was $63,157 and $-0-, respectively, and accrued interest was $197 and $-0-, respectively.

The March 2024 Dent Note III refinanced the previously issued December 2023 Dent Note in the same principal amount of $166,500. Because the two notes were determined to be substantially different, the issuance of the March 2024 Dent Note III and repayment of the December 2023 Dent Note was treated as an extinguishment and reissuance. Accordingly, the Company recognized a loss on debt extinguishment of $96,660 on the transaction date, comprised of $63,539 for the portion of the fair value of the March 2024 Warrant allocated to the March 2024 Dent Note III and $33,121 for the excess of the fair value of the March 2024 Dent Note III over the carrying value of the refinanced December 2023 Dent Note. The March 2024 Dent Note III was recorded at its fair value of $199,621 and will be revalued at future period ends. As of March 31, 2024 and December 31, 2023, remaining principal payments were $166,500 and $-0-, respectively, the carrying value was $199,621 and $-0-, respectively, and accrued interest was $219 and $-0-, respectively.

Interest accrued on notes and convertible notes payable to related parties as of March 31, 2024 and December 31, 2023 was $3,202 and $7,456, respectively. Interest expense on the loans was $3,202 and $3,890 in the three months ended March 31, 2024 and 2023, respectively.

Deferred Compensation Payable to Dr. Michael Dent

There was no activity related to deferred compensation payable to Dr. Michael Dent and therefore, as of March 31, 2024 and December 31, 2023, the balance was $300,600 and $300,600, respectively.

Other Related Transactions

Our outside directors each receive compensation equal to $20,000 in shares of restricted stock per annum. As of March 31, 2024 and December 31, 2023, we had 816,328 and 408,164 shares, respectively, issuable to our directors under such compensation arrangements.

During the three months ended March 31, 2024 and 2023, the Company paid Dr. Dent’s spouse $39,038 and $27,885, respectively, in consulting fees pursuant to a consulting agreement.

22

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 12 – NOTES PAYABLE**

Notes payable as of March 31, 2024 and December 31, 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31,** | |  |  | **December 31,** | |  |
|  |  | **2024** | |  |  | **2023** | |  |
|  |  |  | |  |  |  | |  |
| SBA Disaster Relief Loans |  | $ | 450,000 |  |  | $ | 450,000 |  |
| 1800 Diagonal Note Payable III, August 2023 |  |  | 64,853 |  |  |  | 97,279 |  |
| Yorkville Note Payable III, November 2023 |  |  | 226,800 |  |  |  | 302,400 |  |
| 1800 Diagonal Note Payable III, December 2023 |  |  | 113,482 |  |  |  | 162,131 |  |
| Yorkville Note Payable III, December 2023 |  |  | 162,000 |  |  |  | 189,000 |  |
| Face value of notes payable |  |  | 1,017,135 |  |  |  | 1,200,810 |  |
| Less: unamortized discounts |  |  | (104,288 | ) |  |  | (166,487 | ) |
| Notes payable, total |  |  | 912,847 |  |  |  | 1,034,323 |  |
| Less: long term portion |  |  | (450,000 | ) |  |  | (450,000 | ) |
| Notes payable, current portion |  | $ | 462,847 |  |  | $ | 584,323 |  |

Government Notes Payable

During June, July and August 2020, the Company and its subsidiaries received an aggregate of $450,000 in Disaster Relief Loans from the SBA. The loans bear interest at 3.75% per annum and mature 30 years from issuance. Mandatory principal and interest payments were originally scheduled to begin 12 months from the inception date of each loan and were subsequently extended by the SBA until 30 months from the inception date. Installment payments, which are first applied to accrued but unpaid interest and then to principal, began in 2023.

Interest accrued on SBA loans as of March 31, 2024 and December 31, 2023 was $27,095 and $27,628, respectively. Interest expense on the loans was $6,046 and $4,219 in the three months ended March 31, 2024 and 2023, respectively. Payments against interest were $6,579 and $5,117 in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining principal payments were $450,000 and $450,000, respectively, and the net carrying value was $450,000 and $450,000, respectively.

Other Notes Payable

On July 19, 2022, pursuant to a Note Purchase Agreement between the Company and Yorkville, dated July 5, 2022, the Company issued to Yorkville a promissory note (the “Promissory Note”) with an initial stated principal amount equal to $550,000 at a purchase price equal to the principal amount of the Promissory Note less any original issue discounts and fees. The Promissory Note included a 5% original issue discount, accrues interest at a rate of 0%, and was scheduled to mature on January 19, 2023. The Company received net proceeds of $522,500. Each payment included a 2% payment premium, totaling $561,000 in total cash repayments. At inception, the Company recorded a discount against the note of $38,500, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. On November 15, 2022, the Company and Yorkville entered into an Amended and Restated Note (the “Amended Note”) to, among other things, extend the original note’s maturity date of January 19, 2023 to March 15, 2023. Amortization expense related to the discount was $-0- and $4,748 in the three months ended March 31, 2024 and 2023, respectively. During the three months ended March 31, 2024 and 2023, the Company made payments of $-0- and $168,300 against the Promissory Note, including $18,765 applied from proceeds of sales of common stock under the SEPA. The Amended Note was repaid in March 2023.

23

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 12 – NOTES PAYABLE (CONTINUED)**

On October 21, 2022, the Company issued a promissory note payable to an investor in the principal amount of $144,760 (the “October 2022 Note”). The October 2022 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The October 2022 Note did not bear interest in excess of the original issue discount and had a maturity date of October 31, 2023. The Company was required to make 10 monthly payments of $16,213 starting November 30, 2022 and ending August 31, 2023. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which was amortized over the repayment period. During the three months ended March 31, 2024 and 2023, amortization expense related to the note discount was $-0- and $10,745, respectively, and the Company made payments of $-0- and $32,426, respectively, against the outstanding balance. The October 2022 Note was repaid in August 2023.

On March 10, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $116,760 and prepaid interest of $14,011 for total repayments of $130,771 (the “March 2023 Note”). The March 2023 Note had an original issue discount of $12,510 and fees of $4,250, resulting in net proceeds to the Company of $100,000. The March 2023 Note did not bear interest in excess of the original issue discount and matured on March 10, 2024. The Company was required to make 10 monthly payments of $13,077 starting April 30, 2023. At inception, the Company recorded a discount against the note of $30,771, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the note discount was $-0- and $1,529 in the three months ended March 31, 2024 and 2023, respectively. The Company made no payments against the outstanding balance in the three months ended March 31, 2024 or 2023. The final installment payment was made in December 2023.

On November 4, 2022, AEU borrowed a gross amount of $41,009 from a third-party lender, receiving net proceeds of $35,800 after fees and discounts (the “AEU Loan”). At inception of the note, the Company recognized a discount of $5,209. During the three months ended March 31, 2024 and 2023, amortization expense related to the note discount was $-0- and $2,367, respectively, and the Company made payments of $-0- and $18,632, respectively, against the outstanding balance. The AEU Loan was repaid in June 2023.

On August 8, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the “August 2023 Note”). The August 2023 Note had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The August 2023 Note does not bear interest in excess of the original issue discount and matures on June 30, 2024. The Company is required to make 10 monthly payments of $16,213 starting September 30, 2023 and ending on June 30, 2024. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the note discount was $10,365 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $32,426 and $-0- in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining payments were $64,853 and $97,279, respectively, and the net carrying value was $54,488 and $76,549, respectively. The August 2023 Note gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. As of March 31, 2024, the August 2023 Note was not in default and the Company was in compliance with the stated loan requirements.

On November 3, 2023, the Company issued to Yorkville a note payable (the “November 2023 Note”) with an initial principal amount equal to $350,000 at a purchase price equal to the principal amount of the November 2023 Note less any original issue discounts and fees. The Company received net proceeds of $317,000. The November 2023 Note is scheduled to mature on September 3, 2024. The November 2023 Note accrues interest at a rate of 0% but was issued with an 8% original issue discount and is scheduled to be repaid in ten equal semi-monthly installments beginning on December 3, 2023, with each payment including an 8% payment premium, totaling $378,000 in cash repayments. At inception, the Company recorded a discount against the note of $61,000, representing the difference between the total required repayments and the net proceeds received, which was being amortized over the repayment period. Amortization expense related to the note discount was $18,200 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $75,600 and $-0- in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining payments were $226,800 and $302,400, respectively, and the net carrying value was $195,600 and $253,000, respectively.

24

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 12 – NOTES PAYABLE (CONTINUED)**

On December 12, 2023, the Company issued a promissory note payable to an investor with a stated principal amount of $144,760 and prepaid interest of $17,371 for total repayments of $162,131 (the “December 2023 Note I”). The December 2023 Note I had an original issue discount of $15,510 and fees of $4,250, resulting in net proceeds to the Company of $125,000. The December 2023 Note I does not bear interest in excess of the original issue discount and matures on October 15, 2024. The Company is required to make 10 monthly payments of $16,213 starting January 15, 2024 and ending on October 15, 2024. At inception, the Company recorded a discount against the note of $37,131, representing the difference between the total required repayments and the net proceeds received, which is being amortized over the repayment period. Amortization expense related to the note discount was $10,971 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $48,649 and $-0- in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining payments were $113,482 and $162,131, respectively, and the net carrying value was $89,612 and $127,291, respectively. The December 2023 Note I gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default. The Company determined that the fair value of the contingent conversion option was immaterial and therefore did not allocate any value related to the option to the proceeds received. As March 31, 2024, the December 2023 Note I was not in default and the Company was in compliance with the stated loan requirements.

On December 13, 2023, the Company issued to Yorkville a convertible note (the “December 2023 Note II”) with an initial principal amount equal to $175,000 at a purchase price equal to the principal amount of the December 2023 Note II less any original issue discounts and fees. The Company received net proceeds of $156,000. The December 2023 Note II is scheduled to mature on September 3, 2024. The December 2023 Note II accrues interest at a rate of 0% but was issued with an 8% original issue discount and is scheduled to be repaid in ten equal semi-monthly installments beginning on March 3, 2024, with each payment including an 8% payment premium, totaling $189,000 in cash repayments. The December 2023 Note II is convertible at any time at the holder’s option into shares of Company common stock at a fixed conversion price of $0.05 per share. At inception, the Company recorded a discount against the note of $66,000, representing the fair value of the conversion option and the difference between the total required repayments and the net proceeds received. The discount is being amortized over the repayment period. Amortization expense related to the note discount was $22,664 and $-0- in the three months ended March 31, 2024 and 2023, respectively. The Company made payments against the outstanding balance of $27,000 and $-0- in the three months ended March 31, 2024 and 2023, respectively. As of March 31, 2024 and December 31, 2023, remaining payments were $162,000 and $189,000, respectively, and the net carrying value was $123,147 and $127,483, respectively.

**NOTE 13 – SHAREHOLDERS’ EQUITY**

SEPA Advances

On July 5, 2022, the Company entered into the SEPA with Yorkville, pursuant to which the Company shall have the right, but not the obligation, to sell to Yorkville up to 30,000,000 of its shares of common stock, par value $0.0001 per share, at the Company’s request any time during the commitment period commencing on July 5, 2022 and terminating on the earliest of (i) the first day of the month following the 36-month anniversary of the SEPA and (ii) the date on which Yorkville shall have made payment of any advances requested pursuant to the SEPA for shares of the Company’s common stock equal to the commitment amount of 30,000,000 shares of common stock. Each SEPA advance (an “Advance”) may be for a number of shares of common stock with an aggregate value of up to greater of: (i) an amount equal to thirty percent (30%) of the aggregate daily volume traded of the Company’s common stock for the three (3) trading days immediately preceding notice from the Company of an Advance, or (ii) 2,000,000 shares of common stock. The shares would be purchased at 96.0% of the average of the daily volume weighted average price of the Company’s common stock as reported by Bloomberg L.P. during regular trading hours during each of the three consecutive trading days commencing on the trading day following the Company’s submission of an Advance notice to Yorkville and would be subject to certain limitations, including that Yorkville could not purchase any shares that would result in it owning more than 4.99% of the Company’s outstanding common stock at the time of an Advance. On July 11, 2022, the Company filed a Form S-1 registration statement registering up to 30,000,000 shares of common stock underlying the SEPA. The registration statement was declared effective on July 19, 2022.

During the three months ended March 31, 2023, the Company made one Advance under the SEPA, receiving $18,765 in proceeds for the issuance of 225,000 shares of common stock, all of which was applied to the balance of the Yorkville Promissory Note that was repaid in first quarter 2023. No Advances were made during the three months ended March 31, 2024.

25

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 13 – SHAREHOLDERS’ EQUITY (CONTINUED)**

Private Placements

During the three months ended March 31, 2024, the Company sold 5,100,000 shares of common stock to three investors in separate private placement transactions. The Company received $355,000 in proceeds from the sales. In connection with the stock sales, the Company also issued 2,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.17 per share.

During the three months ended March 31, 2023, the Company sold 2,000,000 shares of common stock to one investor in a private placement transaction. The Company received $200,000 in proceeds from the sale. In connection with the stock sale, the Company also issued 1,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.20 per share.

Shares issued to Consultants

During the three months ended March 31, 2024, the Company issued to a consultant a ten-year stock option to purchase 2,504,974 shares of common stock at an exercise price equal of $0.0569 in satisfaction of common stock issuable accrued to the consultant for services provided between 2021 and 2024.

Common Stock Issuable

As of March 31, 2024 and December 31, 2023, the Company was obligated to issue the following shares:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31, 2024** | | | | | |  |  | **December 31, 2023** | | | | | |  |
|  |  | **Amount** | |  |  | **Shares** | |  |  | **Amount** | |  |  | **Shares** | |  |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Shares issuable to employees and consultants |  | $ | 14,570 |  |  |  | 239,208 |  |  | $ | 261,682 |  |  |  | 2,356,188 |  |
| Shares issuable to independent directors |  |  | 40,000 |  |  |  | 816,328 |  |  |  | 20,000 |  |  |  | 408,164 |  |
|  |  | $ | 54,570 |  |  |  | 1,055,536 |  |  | $ | 281,682 |  |  |  | 2,764,352 |  |

Stock Warrants

Transactions involving our stock warrants during the three months ended March 31, 2024 and 2023 are summarized as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2024** | | | | | |  |  | **2023** | | | | | |  |
|  |  |  | |  |  | **Weighted** | |  |  |  | |  |  | **Weighted** | |  |
|  |  |  | |  |  | **Average** | |  |  |  | |  |  | **Average** | |  |
|  |  |  | |  |  | **Exercise** | |  |  |  | |  |  | **Exercise** | |  |
|  |  | **Number** | |  |  | **Price** | |  |  | **Number** | |  |  | **Price** | |  |
| Outstanding at beginning of the period |  |  | 77,414,648 |  |  | $ | 0.20 |  |  |  | 68,109,094 |  |  | $ | 0.23 |  |
| Granted during the period |  |  | 9,160,000 |  |  | $ | 0.09 |  |  |  | 3,141,554 |  |  | $ | 0.15 |  |
| Exercised during the period |  |  | --- |  |  | $ | --- |  |  |  | --- |  |  | $ | --- |  |
| Expired during the period |  |  | (1,217,402 | ) |  | $ | (0.28 | ) |  |  | (2,508,333 | ) |  | $ | (0.25 | ) |
| Outstanding at end of the period |  |  | 85,357,246 |  |  | $ | 0.19 |  |  |  | 68,742,315 |  |  | $ | 0.22 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Exercisable at end of the period |  |  | 85,357,246 |  |  | $ | 0.19 |  |  |  | 68,742,315 |  |  | $ | 0.22 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Weighted average remaining life |  |  | 2.7 years | | | | |  |  |  | 2.5 years | | | | |  |

26

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 13 – SHAREHOLDERS’ EQUITY (CONTINUED)**

The following table summarizes information about the Company’s stock warrants outstanding as of March 31, 2024:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Warrants Outstanding** | | | | | | | | | | | |  |  | **Warrants Exercisable** | | | | | |  |
|  | |  |  |  | |  |  | **Weighted-** |  |  | |  |  |  | |  |  |  | |  |
|  | |  |  |  | |  |  | **Average** |  | **Weighted-** | |  |  |  | |  |  | **Weighted-** | |  |
|  | |  |  |  | |  |  | **Remaining** |  | **Average** | |  |  |  | |  |  | **Average** | |  |
| **Exercise** | |  |  | **Number** | |  |  | **Contractual** |  | **Exercise** | |  |  | **Number** | |  |  | **Exercise** | |  |
| **Prices** | |  |  | **Outstanding** | |  |  | **Life (years)** |  | **Price** | |  |  | **Exercisable** | |  |  | **Price** | |  |
| $ | 0.0001 to 0.09 |  |  |  | 29,968,289 |  |  | 3.6 |  | $ | 0.07 |  |  |  | 29,968,289 |  |  | $ | 0.07 |  |
| $ | 0.10 to 0.24 |  |  |  | 25,436,940 |  |  | 3.0 |  | $ | 0.16 |  |  |  | 25,436,940 |  |  | $ | 0.16 |  |
| $ | 0.25 to 0.49 |  |  |  | 26,992,093 |  |  | 1.5 |  | $ | 0.31 |  |  |  | 26,992,093 |  |  | $ | 0.31 |  |
| $ | 0.50 to 1.05 |  |  |  | 2,959,924 |  |  | 2.3 |  | $ | 0.68 |  |  |  | 2,959,924 |  |  | $ | 0.68 |  |
| $ | 0.05 to 1.00 |  |  |  | 85,357,246 |  |  | 2.7 |  | $ | 0.19 |  |  |  | 85,357,246 |  |  | $ | 0.19 |  |

During the three months ended March 31, 2024 and 2023, the Company issued 9,160,000 and 3,141,554 warrants, respectively, the aggregate grant date fair value of which was $385,633 and $246,063, respectively. The fair value of the warrants was calculated using the following range of assumptions:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **2024** |  | **2023** |
| Pricing model utilized |  | Binomial Lattice |  | Binomial Lattice |
| Risk free rate range |  | 3.97% to 4.20% |  | 3.45% to 5.43% |
| Expected life range (in years) |  | 5.00 years to 10.00 years |  | 0.28 years to 5.00 years |
| Volatility range |  | 140.94% to 173.25% |  | 126.30% to 165.20% |
| Dividend yield |  | 0.00% |  | 0.00% |
| Expected forfeiture |  | 33.00% |  | 20.00% |

There were no warrants exercised during the three months ended March 31, 2024 or 2023.

Equity Incentive Plans

On January 1, 2016, the Company adopted the 2016 Equity Incentive Plan (the “2016 EIP”) for the purpose of having equity awards available to allow for equity participation by its employees, consultants and non-employee directors. The 2016 EIP allowed for the issuance of up to 15,503,680 shares of the Company’s common stock, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2016 EIP is governed by the Board, or a committee that may be appointed by the Board in the future. The 2016 EIP expired during 2021 but allows for the prospective issuance of common shares upon vesting of stock awards or exercise of stock options granted prior to expiration of the 2016 EIP.

On September 9, 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 EIP” and, together with the 2016 EIP, the “EIPs”) for the purpose of having equity awards available to allow for equity participation by its employees, consultants and non-employee directors. The 2021 EIP allows for the issuance of up to 20,000,000 shares of the Company’s common stock, which may be issued in the form of stock options, stock appreciation rights, or common shares. The 2021 EIP is governed by the Board, or a committee that may be appointed by the Board in the future.

27

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 13 – SHAREHOLDERS’ EQUITY (CONTINUED)**

Amounts recognized in the financial statements with respect to the EIPs in the three months ended March 31, 2024 and 2023 were as follows:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| Total cost of share-based payment plans during the period |  | $ | 35,986 |  |  | $ | 82,951 |  |
| Amounts capitalized in deferred equity compensation during period |  | $ | --- |  |  | $ | --- |  |
| Amounts written off from deferred equity compensation during period |  | $ | 57,147 |  |  | $ | --- |  |
| Amounts charged against income for amounts previously capitalized |  | $ | --- |  |  | $ | 5,150 |  |
| Amounts charged against income, before income tax benefit |  | $ | 93,133 |  |  | $ | 88,101 |  |
| Amount of related income tax benefit recognized in income |  | $ | --- |  |  | $ | --- |  |

*Stock Options*

Stock options granted under the EIPs typically vest over a period of three to four years or based on achievement of Company and individual performance goals. The following table summarizes stock option activity as of and for the three months ended March 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2024** | | | | | |  |  | **2023** | | | | | |  |
|  |  |  | |  |  | **Weighted** | |  |  |  | |  |  | **Weighted** | |  |
|  |  |  | |  |  | **Average** | |  |  |  | |  |  | **Average** | |  |
|  |  |  | |  |  | **Exercise** | |  |  |  | |  |  | **Exercise** | |  |
| ***Stock options*** |  | **Number** | |  |  | **Price** | |  |  | **Number** | |  |  | **Price** | |  |
| Outstanding at beginning of period |  |  | 5,093,738 |  |  | $ | 0.16 |  |  |  | 5,222,982 |  |  | $ | 0.20 |  |
| Granted during the period |  |  | 4,504,974 |  |  | $ | 0.06 |  |  |  | 93,750 |  |  | $ | 0.08 |  |
| Exercised during the period |  |  | --- |  |  | $ | --- |  |  |  | --- |  |  | $ | --- |  |
| Forfeited during the period |  |  | (449,982 | ) |  | $ | (0.21 | ) |  |  | (150,000 | ) |  | $ | (0.16 | ) |
| Outstanding at end of period |  |  | 9,148,730 |  |  | $ | 0.10 |  |  |  | 5,166,732 |  |  | $ | 0.17 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Options exercisable at period-end |  |  | 7,063,146 |  |  | $ | 0.11 |  |  |  | 3,108,565 |  |  | $ | (0.20 | ) |

As of March 31, 2024, there was $78,222 of total unrecognized compensation cost related to options granted under the EIPs. That cost is expected to be recognized over a weighted-average period of 1.7 years.

The weighted-average grant-date fair value of options granted during the three months ended March 31, 2024 and 2023 was $0.04 and $0.05, respectively. The total fair value of options vested during the three months ended March 31, 2024 and 2023 was $137,040 and $26,845, respectively. No options were exercised during the three months ended March 31, 2024 or 2023. Stock based compensation expense related to stock options was $47,900 and $22,511 in the three months ended March 31, 2024 and 2023, respectively.

28

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 13 – SHAREHOLDERS’ EQUITY (CONTINUED)**

The fair value of each stock option award is estimated on the date of grant using a binomial lattice option-pricing model based on the assumptions noted in the following table. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period. The fair value of options granted for the three months ended March 31, 2024 and 2023 was calculated using the following range of assumptions:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | **2024** |  | **2023** |
| Pricing model utilized |  | Binomial Lattice |  | Binomial Lattice |
| Risk free rate range |  | 4.20% |  | 3.48% |
| Expected life range (in years) |  | 10.00 years |  | 10.00 years |
| Volatility range |  | 173.25% |  | 145.03% |
| Dividend yield |  | 0.00% |  | 0.00% |
| Expected forfeiture |  | 30.00% |  | 30.00% |

The following table summarizes the status and activity of nonvested options issued pursuant to the EIPs as of and for the three months ended March 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2024** | | | | | |  |  | **2023** | | | | | |  |
|  |  |  | |  |  | **Weighted** | |  |  |  | |  |  | **Weighted** | |  |
|  |  |  | |  |  | **Average** | |  |  |  | |  |  | **Average** | |  |
|  |  |  | |  |  | **Grant Date** | |  |  |  | |  |  | **Grant Date** | |  |
| ***Stock options*** |  | **Shares** | |  |  | **Fair Value** | |  |  | **Shares** | |  |  | **Fair Value** | |  |
| Nonvested options at beginning of period |  |  | 1,073,084 |  |  | $ | 0.06 |  |  |  | 2,260,417 |  |  | $ | 0.08 |  |
| Granted |  |  | 4,504,974 |  |  | $ | 0.04 |  |  |  | 93,750 |  |  | $ | 0.05 |  |
| Vested |  |  | (3,442,474 | ) |  | $ | (0.04 | ) |  |  | (196,000 | ) |  | $ | (0.14 | ) |
| Forfeited |  |  | (50,000 | ) |  | $ | (0.08 | ) |  |  | (100,000 | ) |  | $ | (0.09 | ) |
| Nonvested options at end of period |  |  | 2,085,584 |  |  | $ | 0.05 |  |  |  | 2,058,167 |  |  | $ | 0.07 |  |

*Stock Grants*

Stock grant awards made under the EIPs typically vest either immediately or over a period of up to four years. The following table summarizes stock grant activity as of and for the three months ended March 31, 2024 and 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **2024** | | | | | |  |  | **2023** | | | | | |  |
|  |  |  | |  |  | **Weighted** | |  |  |  | |  |  | **Weighted** | |  |
|  |  |  | |  |  | **Average** | |  |  |  | |  |  | **Average** | |  |
|  |  |  | |  |  | **Grant Date** | |  |  |  | |  |  | **Grant Date** | |  |
| ***Stock Grants*** |  | **Shares** | |  |  | **Fair Value** | |  |  | **Shares** | |  |  | **Fair Value** | |  |
| Nonvested grants at beginning of period |  |  | 1,484,488 |  |  | $ | 0.05 |  |  |  | 1,651,435 |  |  | $ | 0.05 |  |
| Granted |  |  | --- |  |  | $ | --- |  |  |  | 160,944 |  |  | $ | 0.09 |  |
| Vested |  |  | (408,164 | ) |  | $ | (0.05 | ) |  |  | (468,292 | ) |  | $ | (0.05 | ) |
| Forfeited |  |  | (50,000 | ) |  | $ | (0.12 | ) |  |  | --- |  |  | $ | --- |  |
| Nonvested grants at end of period |  |  | 1,026,324 |  |  | $ | 0.05 |  |  |  | 1,344,087 |  |  | $ | 0.06 |  |

As of March 31, 2024, there was $10,449 of total unrecognized compensation cost related to stock grants made under the EIPs. That cost is expected to be recognized over a weighted-average period of 1.5 years. The weighted-average grant-date fair value of share grants made during the three months ended March 31, 2023 was $0.09 per share. No grants were made in the three months ended March 31, 2024. The aggregate fair value of share grants that vested during the three months ended March 31, 2024 and 2023 was $20,000 and $22,460, respectively. Stock based compensation expense related to stock grants was $1,796 and $25,467 in the three months ended March 31, 2024 and 2023, respectively.

29

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 13 – SHAREHOLDERS’ EQUITY (CONTINUED)**

The fair value of each stock grant is calculated using the closing sale price of the Company’s common stock on the date of grant. The Company’s accounting policy is to estimate forfeitures in determining the amount of total compensation cost to record each period.

*Liability-Classified Equity Instruments*

During 2021, the Company made certain stock grants from the 2021 EIP that vest over a four-year period and that are settleable for a fixed dollar amount rather than a fixed number of shares. During 2022, the Company made an additional grant of stock options from the 2021 EIP with a fixed fair value that may be earned based on achievement of performance targets on a quarterly basis through June 2025. The Company recognized an asset captioned “Deferred equity compensation” and an offsetting liability captioned as a “Liability-classified equity instrument” related to such instruments. Amortization of deferred stock compensation assets in the three months ended March 31, 2024 and 2023 was $-0- and $5,150, respectively. The liability will be converted to equity if and when shares are earned and issued pursuant to prescribed vesting events. The Company subsequently de-recognized Deferred equity compensation and Liability-classified equity instruments upon termination of the instruments in 2022 and 2023 and no further equity-related assets or liabilities remained as of March 31, 2024.

**NOTE 14 – COMMITMENTS AND CONTINGENCIES**

Supplier Concentration

The Company relied on a single supplier for the fulfillment of approximately 91% and 95% of its product sales made through MOD in the three months ended March 31, 2024 and 2023, respectively.

Service Contracts

The Company carries various service contracts on its office buildings and certain copier equipment for repairs, maintenance and inspections. All contracts are short term and can be cancelled.

Leases

Maturities of operating lease liabilities were as follows as of March 31, 2024:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 2024 |  | $ | 390,027 |  |
| 2025 |  |  | 467,994 |  |
| 2026 |  |  | 335,634 |  |
| 2027 |  |  | 990 |  |
| Total lease payments |  |  | 1,194,645 |  |
| Less interest |  |  | (337,407 | ) |
| Present value of lease liabilities |  | $ | 857,238 |  |

Employment/Consulting Agreements

The Company has employment agreements with certain of its physicians, nurse practitioners and physical therapists in the Health Services Division. The agreements generally call for a fixed salary plus performance-based pay.

On March 1, 2024, the Company entered into an offer letter agreement with David Rosal, Chief Financial Officer of the Company. The agreement was effective as of March 11, 2024 and provides that Mr. Rosal’s base salary will be $150,000 per year. Mr. Rosal is eligible to receive grants from the Company’s Employee Stock Option Plan. Mr. Rosal’s employment is at-will with no defined contractual employment period.

30

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 14 – COMMITMENTS AND CONTINGENCIES (CONTINUED)**

On July 1, 2016, the Company entered into an employment agreement with Dr. Michael Dent, Chief Executive Officer and a member of the Board of Directors. Dr. Dent’s employment agreement continues until terminated by Dr. Dent or the Company. If Dr. Dent’s employment is terminated by the Company (unless such termination is “For Cause” as defined in his employment agreement), then upon signing a general waiver and release, Dr. Dent will be entitled to severance in an amount equal to 12 months of his then-current annual base salary, as well as the pro-rata portion of any bonus that would be due and payable to him. In the event that Dr. Dent terminates the employment agreement, he shall be entitled to any accrued but unpaid salary and other benefits up to and including the date of termination, and the pro-rata portion of any unvested time-based options up until the date of termination.

Litigation

From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. The Company is not aware of any such legal proceedings that will have, individually or in the aggregate, a material adverse effect on its business, financial condition or operating results.

**NOTE 15 – SEGMENT REPORTING**

As of March 31, 2024, the Company had three reportable segments: Health Services, Digital Healthcare, and Medical Distribution. The Health Services Division is comprised of the operations of (i) NWC, a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology), and General Practice, (ii) NCFM, a Functional Medical Practice acquired in April 2019 that is engaged in improving the health of its patients through individualized and integrative health care, (iii) BTG, a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, and (iv) AEU, a patient service facility specializing in minimally and non-invasive cosmetic services acquired by the Company in May 2022. The Digital Healthcare segment develops and plans to operate an online personal medical information and record archive system, the “HealthLynked Network,” which will enable patients and doctors to keep track of medical information via the Internet in a cloud-based system. The Medical Distribution Division is comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States.

On January 17, 2023, the Company entered into the AHP Merger Agreement pursuant to which the Company sold AHP and discontinued the operations of CHM, comprising its ACO/MSO Division. The Company has classified the results of the ACO/MSO Division as discontinued operations in the accompanying consolidated statement of operations for all periods presented. See Note 4, “Discontinued Operations,” for additional information.

The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.

31

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 15 – SEGMENT REPORTING (CONTINUED)**

Segment information for the year ended three months ended March 31, 2024 was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months ended March 31, 2024** | | | | | | | | | | | | | |  |
|  |  | **Health Services** | |  |  | **Digital Healthcare** | |  |  | **Medical Distribution** | |  |  | **Total** | |  |
| **Revenue** |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Patient service revenue, net |  | $ | 963,621 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 963,621 |  |
| Subscription revenue |  |  | --- |  |  |  | 7,628 |  |  |  | --- |  |  |  | 7,628 |  |
| Product and other revenue |  |  | --- |  |  |  | --- |  |  |  | 32,983 |  |  |  | 32,983 |  |
| Total revenue |  |  | 963,621 |  |  |  | 7,628 |  |  |  | 32,983 |  |  |  | 1,004,232 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Operating Expenses** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Practice salaries and benefits |  |  | 583,156 |  |  |  | --- |  |  |  | --- |  |  |  | 583,156 |  |
| Other practice operating expenses |  |  | 482,583 |  |  |  | --- |  |  |  | --- |  |  |  | 482,583 |  |
| Cost of product revenue |  |  | --- |  |  |  | --- |  |  |  | 30,579 |  |  |  | 30,579 |  |
| Selling, general and administrative expenses |  |  | --- |  |  |  | 980,174 |  |  |  | 19,269 |  |  |  | 999,443 |  |
| Depreciation and amortization |  |  | 85,169 |  |  |  | 1,340 |  |  |  | --- |  |  |  | 86,509 |  |
| Total Operating Expenses |  |  | 1,150,908 |  |  |  | 981,514 |  |  |  | 49,848 |  |  |  | 2,182,270 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from operations |  | $ | (187,287 | ) |  | $ | (973,886 | ) |  | $ | (16,865 | ) |  | $ | (1,178,038 | ) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Other Segment Information** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss on extinguishment of debt |  | $ | --- |  |  | $ | 96,660 |  |  | $ | --- |  |  | $ | 96,660 |  |
| Amortization of original issue discounts on notes payable |  | $ | 108,265 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 108,265 |  |
| Change in fair value of contingent acquisition consideration |  | $ | --- |  |  | $ | (76 | ) |  | $ | --- |  |  | $ | (76 | ) |
| Interest expense |  | $ | 3,881 |  |  | $ | 950 |  |  | $ | --- |  |  | $ | 4,831 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Identifiable Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Identifiable assets as of March 31, 2024 |  | $ | 1,635,387 |  |  | $ | 2,246,600 |  |  | $ | 8,772 |  |  | $ | 3,890,759 |  |
| Identifiable assets as of December 31, 2023 |  | $ | 1,812,609 |  |  | $ | 2,457,849 |  |  | $ | 9,682 |  |  | $ | 4,280,140 |  |

32

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 15 – SEGMENT REPORTING (CONTINUED)**

Segment information for the three months ended three months ended March 31, 2023 was as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31, 2023** | | | | | | | | | | | | | |  |
|  |  | **Health Services** | |  |  | **Digital Healthcare** | |  |  | **Medical Distribution** | |  |  | **Total** | |  |
| **Revenue** |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Patient service revenue, net |  | $ | 1,700,281 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 1,700,281 |  |
| Subscription revenue |  |  | --- |  |  |  | 16,299 |  |  |  | --- |  |  |  | 16,299 |  |
| Product and other revenue |  |  | --- |  |  |  | --- |  |  |  | 38,574 |  |  |  | 38,574 |  |
| Total revenue |  |  | 1,700,281 |  |  |  | 16,299 |  |  |  | 38,574 |  |  |  | 1,755,154 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Operating Expenses** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Practice salaries and benefits |  |  | 963,657 |  |  |  | --- |  |  |  | --- |  |  |  | 963,657 |  |
| Other practice operating expenses |  |  | 624,247 |  |  |  | --- |  |  |  | --- |  |  |  | 624,247 |  |
| Cost of product revenue |  |  | --- |  |  |  | --- |  |  |  | 32,060 |  |  |  | 32,060 |  |
| Selling, general and administrative expenses |  |  | --- |  |  |  | 1,070,321 |  |  |  | 33,427 |  |  |  | 1,103,748 |  |
| Depreciation and amortization |  |  | 86,672 |  |  |  | 1,405 |  |  |  | --- |  |  |  | 88,077 |  |
| Total Operating Expenses |  |  | 1,674,576 |  |  |  | 1,071,726 |  |  |  | 65,487 |  |  |  | 2,811,789 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Income (loss) from operations |  | $ | 25,705 |  |  | $ | (1,055,427 | ) |  | $ | (26,913 | ) |  | $ | (1,056,635 | ) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Other Segment Information** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Interest expense (income) |  | $ | --- |  |  | $ | 44,763 |  |  | $ | --- |  |  | $ | 44,763 |  |
| Financing cost |  | $ | 2,812 |  |  | $ | 8,569 |  |  | $ | --- |  |  | $ | 11,381 |  |
| Amortization of original issue discounts on notes payable |  | $ | 60,993 |  |  | $ | 2,367 |  |  | $ | --- |  |  | $ | 63,360 |  |
| Change in fair value of contingent acquisition consideration |  | $ | --- |  |  | $ | 1,706 |  |  | $ | --- |  |  | $ | 1,706 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Identifiable Assets** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Identifiable assets as of March 31, 2023 |  | $ | 2,204,934 |  |  | $ | 3,606,105 |  |  | $ | 14,203 |  |  | $ | 5,825,242 |  |
| Goodwill as of March 31, 2023 |  | $ | 319,958 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 319,958 |  |

The Digital Healthcare Division made intercompany sales of $180 and $180 in the three months ended March 31, 2024 and 2023, respectively, related to subscription revenue billed to and paid for by the Company’s physicians for access to the HealthLynked Network. The Medical Distribution segment made intercompany sales of $-0- and $8,340 in the three months ended March 31, 2024 and 2023, respectively, related to medical products sold to practices in the Company’s Health Services segment. Intercompany revenue and the related costs are eliminated on consolidation.

**NOTE 16 – FAIR VALUE OF FINANCIAL INSTRUMENTS**

The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, approximate their respective fair values due to the short-term nature of such instruments. The Company measures certain financial instruments at fair value on a recurring basis, including certain convertible notes payable and related party loans, which were extinguished and reissued and are therefore subject to fair value measurement, derivative financial instruments arising from conversion features embedded in convertible promissory notes for which the conversion rate was not fixed, and equity-class. All financial instruments carried at fair value fall within Level 3 of the fair value hierarchy as their value is based on unobservable inputs. The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made.

33

**HEALTHLYNKED CORP.**

**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**MARCH 31, 2024 (UNAUDITED)**

**NOTE 16 – FAIR VALUE OF FINANCIAL INSTRUMENTS (CONTINUED)**

The following table summarizes the conclusions reached regarding fair value measurements as of March 31, 2024 and December 31, 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **As of March 31, 2024** | | | | | | | | | | | | | |  |  | **As of December 31, 2023** | | | | | | | | | | | | | |  |
|  |  | **Level 1** | |  |  | **Level 2** | |  |  | **Level 3** | |  |  | **Total** | |  |  | **Level 1** | |  |  | **Level 2** | |  |  | **Level 3** | |  |  | **Total** | |  |
| ***Assets:*** |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Contingent sale consideration receivable |  | $ | --- |  |  | $ | --- |  |  | $ | 1,663,163 |  |  | $ | 1,663,163 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 1,663,163 |  |  | $ | 1,663,163 |  |
| ***Liabilities:*** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Contingent acquisition consideration payable |  |  | --- |  |  |  | --- |  |  |  | 2,113 |  |  |  | 2,113 |  |  |  | --- |  |  |  | --- |  |  |  | 2,189 |  |  |  | 2,189 |  |
| Convertible note payable to related party |  |  | --- |  |  |  | --- |  |  |  | 199,621 |  |  |  | 199,621 |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |  |  | --- |  |
|  |  | $ | --- |  |  | $ | --- |  |  | $ | 201,734 |  |  | $ | 201,734 |  |  | $ | --- |  |  | $ | --- |  |  | $ | 2,189 |  |  | $ | 2,189 |  |

Contingent acquisition consideration payable is a Level 3 financial instrument that is measured at fair value on a recurring basis. Gains (losses) from the change in fair value of contingent acquisition consideration payable were $76 and ($1,706) during the three months ended March 31, 2024 and 2023, respectively.

**NOTE 17 – SUBSEQUENT EVENTS**

On April 10, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of October 10, 2024. The convertible note payable is convertible at any time at the holder’s option into shares of the Company common stock at a fixed conversion price of $0.0577 per share.

On April 12, 2024, the Company sold 877,193 shares of common stock for cash in a private placement transaction to an accredited investor. The Company received $50,000 in proceeds from the sale. In connection with the stock sale, the Company also issued 438,596 five-year warrants to purchase shares of common stock at an exercise price of $0.16 per share.

On April 18, 2024, the Company issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $50,000, an interest rate of 12% per annum, and a maturity date of October 18, 2024. The convertible note payable is convertible at any time at the holder’s option into shares of the Company common stock at a fixed conversion price of $0.05 per share.

On April 22, 2024, the Company issued a promissory note payable to an investor with a stated principal amount of $161,000 and prepaid interest of $19,320 for total repayments of $180,320. The Company received net proceeds of $118,787 after original issue discount of $21,000, fees of $5,000, and withholding of the final payment due on the August 2023 Note to the same investor in the amount of $16,213. The note does not bear interest in excess of the original issue discount and prepaid interest and matures on February 28, 2025. The Company is required to make 10 monthly payments of $18,032 starting May 30, 2024 and ending on February 28, 2025. The note gives the holder a conversion right at a 15% discount to the market price of the Company’s common stock in the event of default.

On May 6 and May 8, 2024, a trust controlled by Dr. Michael Dent advanced $100,000 and $70,000, respectively, to the Company. The advances are expected to be documented in formal debt agreements in the second quarter of 2024.

34

**Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations**

**Forward-Looking Statements**

*You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this report. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Item 1A. Risk Factors” included in our most recent Annual Report on Form 10-K. All amounts in this report are in U.S. dollars, unless otherwise noted.*

**Overview**

General

HealthLynked Corp. (the “Company,” “we,” “our,” or “us”) was incorporated in the State of Nevada on August 4, 2014. We currently operate in three distinct divisions: the Health Services Division, the Digital Healthcare Division, and the Medical Distribution Division. Our Health Services Division is comprised of the operations of (i) Naples Women’s Center (“NWC”), a multi-specialty medical group including OB/GYN (both Obstetrics and Gynecology) and General Practice, (ii) Naples Center for Functional Medicine (“NCFM”), a Functional Medical Practice engaged in improving the health of its patients through individualized and integrative health care, (iii) BTG, a physical therapy practice in Bonita Springs, Florida that provides hands-on functional manual therapy techniques to speed patients’ recovery and manage pain without pain medication or surgery, and (iv) AEU, a patient service facility specializing in minimally and non-invasive cosmetic services acquired by the Company in May 2022. Our Digital Healthcare Division develops and operates an online personal medical information and record archive system, the “HealthLynked Network,” which enables patients and doctors to keep track of medical information via the Internet in a cloud-based system. Our Medical Distribution Division is comprised of the operations of MOD, a virtual distributor of discounted medical supplies selling to both consumers and medical practices throughout the United States.

**Critical accounting policies and significant judgments and estimates**

For a discussion of our critical accounting policies, see Note 2, “*Significant Accounting Policies,”* in the Notes to the condensed consolidated financial statements.

35

**Results of Operations**

Comparison of Three Months Ended March 31, 2024 and 2023

The following table summarizes the changes in our results of operations for the three months ended March 31, 2024 compared with the three months ended March 31, 2023:

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |  | **Change** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |  | **$** | |  |  | **%** | |  |
|  |  |  | |  |  |  | |  |  |  | |  |  |  | |  |
| Patient service revenue, net |  | $ | 963,621 |  |  | $ | 1,700,281 |  |  | $ | (736,660 | ) |  |  | -43 | % |
| Subscription revenue |  |  | 7,628 |  |  |  | 16,299 |  |  |  | (8,671 | ) |  |  | -53 | % |
| Product revenue |  |  | 32,983 |  |  |  | 38,574 |  |  |  | (5,591 | ) |  |  | -14 | % |
| Total revenue |  |  | 1,004,232 |  |  |  | 1,755,154 |  |  |  | (750,922 | ) |  |  | -43 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Operating Expenses and Costs** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Practice salaries and benefits |  |  | 583,156 |  |  |  | 963,657 |  |  |  | (380,501 | ) |  |  | -39 | % |
| Other practice operating expenses |  |  | 482,583 |  |  |  | 624,247 |  |  |  | (141,664 | ) |  |  | -23 | % |
| Cost of product revenue |  |  | 30,579 |  |  |  | 32,060 |  |  |  | (1,481 | ) |  |  | -5 | % |
| Selling, general and administrative expenses |  |  | 999,443 |  |  |  | 1,103,748 |  |  |  | (104,305 | ) |  |  | -9 | % |
| Depreciation and amortization |  |  | 86,509 |  |  |  | 88,077 |  |  |  | (1,568 | ) |  |  | -2 | % |
| Loss from operations |  |  | (1,178,038 | ) |  |  | (1,056,635 | ) |  |  | (121,403 | ) |  |  | 11 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Other Income (Expenses)** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss on extinguishment of debt |  |  | (96,660 | ) |  |  | (44,763 | ) |  |  | (51,897 | ) |  |  | 116 | % |
| Amortization of original issue discounts on notes payable |  |  | (108,265 | ) |  |  | (63,360 | ) |  |  | (44,905 | ) |  |  | 71 | % |
| Change in fair value of contingent acquisition consideration |  |  | 76 |  |  |  | (1,706 | ) |  |  | 1,782 |  |  |  | -104 | % |
| Interest expense |  |  | (4,831 | ) |  |  | (11,381 | ) |  |  | 6,550 |  |  |  | -58 | % |
| Total other income (expenses) |  |  | (209,680 | ) |  |  | (121,210 | ) |  |  | (88,470 | ) |  |  | 73 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss from continuing operations |  |  | (1,387,718 | ) |  |  | (1,177,845 | ) |  |  | (209,873 | ) |  |  | 18 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Gain (loss) from operations of discontinued operations** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Loss from operations of discontinued operations |  |  | --- |  |  |  | (44,289 | ) |  |  | 44,289 |  |  |  | -100 | % |
| Gain from disposal of discontinued operations |  |  | --- |  |  |  | 2,674,069 |  |  |  | (2,674,069 | ) |  |  | -100 | % |
| Gain (loss) on discontinued operations |  |  | --- |  |  |  | 2,629,780 |  |  |  | (2,629,780 | ) |  |  | -100 | % |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| **Net income (loss)** |  | $ | (1,387,718 | ) |  | $ | 1,451,935 |  |  | $ | (2,839,653 | ) |  |  | -196 | % |

\* - Denotes line item on statement of operations for which there was no corresponding activity in the same period of prior year.

*Revenue*

Patient service revenue in the three months ended March 31, 2024 decreased by $736,660, or 43% year-over-year, from $1,700,281, to $963,261, primarily as a result of (i) a 45% year-over-year decrease at our NCFM practice of $582,785 due to changes in clinical staffing that saw the departure of three physicians in 2023, two of which have been replaced and one more which is expected to be replaced in the second quarter of 2024, (ii) a 93% year-over-year decrease at our AEU practice of $107,385 due to the departure of our primary physician, and (iii) a 33% decrease at our practice facility of $70,183, offset by (iv) 28% increase of $23,694 at our BTG practice. The reduction in revenue was offset in part by a corresponding designed reduction in practice operating costs as described below in the fluctuation of “Practice salaries and benefits” and “Other practice operating costs,” which declined by a combined $522,165 from 2023 to 2024. While we expect patient service revenue to increase in future periods from levels realized in the three months ended March 31, 2024 as we add an additional physician and continue patient marketing and retention efforts, there is no guarantee that such increases will occur.

Subscription revenue in the three months ended March 31, 2024 decreased by $8,671, or 53% year-over-year, to $7,628, from $16,299, due primarily to a decrease in HealthLynked Network paid subscriptions that were paired with NCFM membership contracts.

36

Product revenue was $32,983 in the three months ended March 31, 2024, compared to $38,574 in the three months ended March 31, 2023, a decrease of $5,591, or 14%. Product revenue was earned by the Medical Distribution Division, comprised of the operations of MOD.

*Operating Expenses and Costs*

Practice salaries and benefits decreased by $380,501, or 39%, to $583,156 in the three months ended March 31, 2024, compared to $963,657 in the three months ended March 31, 2023, primarily as a result of focused cost reduction efforts at all of our practices starting in mid-2023.

Other practice operating costs decreased by $141,664 or 23%, to $482,583 in the three months ended March 31, 2024 from $624,247 in the three months ended March 31, 2023, primarily as a result of focused cost reduction efforts at all of our practices starting in mid-2023.

Cost of product revenue was $30,579 in the three months ended March 31, 2024, a decrease of $1,481, or 5%, compared to $32,060 in the same period of 2023, corresponding to the decline in product sales for the period compared to the same period in the prior year.

Selling, general and administrative costs decreased by $104,305, or 9%, to $999,443 in the three months ended March 31, 2024 compared to $1,103,748 in the three months ended March 31, 2023, primarily due to lower legal, consulting, and other overhead costs in our corporate function resulting from focused cost cutting efforts.

Depreciation and amortization in the three months ended March 31, 2024 decreased by $1,568, or 2%, to $86,509 compared to $88,077 in the three months ended March 31, 2023, primarily as a result of certain fixed asset reaching the end of their depreciable lives during 2023.

Loss from operations increased by $121,403, or 11%, to $1,178,038 in the three months ended March 31, 2024 compared to $1,056,635 in the three months ended March 31, 2023, primarily as a result of the decrease in revenue, offset in part by reduced practice operating costs and corporate overhead costs.

*Other Income (Expenses)*

Loss on extinguishment of debt in the three months ended March 31, 2023 was $44,763 resulting from early repayment of notes payable to our CEO and Chairman, Dr. Dent, representing the excess of the repayment amount over the carrying value (net of unamortized discounts) of the debt instruments at the time of repayment. Loss on extinguishment of debt in the three months ended March 31, 2024 was $96,660 resulting from a maturing note payable to Dr. Dent refinanced with a new convertible note payable in the same amount.

Amortization of original issue and debt discounts on notes payable and convertible notes in the three months ended March 31, 2024 was $108,265, an increase of $44,905, or 71%, compared to $63,360 in the three months ended March 31, 2023. Amortization of discounts arose from original issue discounts on notes payable, warrants attached to notes payable, and beneficial conversion features in convertible notes payable. The increase was due to higher notes payable balances, and therefore corresponding amortizable discount balances, in 2024 compared to 2023.

Gain (loss) from the change in fair value of contingent acquisition consideration increased by $1,782, or -104%, to a gain of $76 in the three months ended March 31, 2024, compared to a loss of ($1,706) in the three months ended March 31, 2023. These charges relate to the fourth and final year of the MOD earnout, which will resolve based on the performance of our Medical Distribution Division in calendar year 2024.

Interest expense decreased by $6,550, or 58%, to $4,831 for the three months ended March 31, 2024, compared to $11,381 in the three months ended March 31, 2023, due to a decrease in interest-bearing notes payable to related parties and third parties during the first quarter of 2024 compared to the same period of 2023.

Total other income (expenses) increased by $88,470, or 73%, to net expense of $209,680 in the three months ended March 31, 2024 compared to net expense of $121,210 in the three months ended March 31, 2023. The change was primarily a result of increased debt discount amortization charges in 2024 corresponding to higher debt balances and higher debt extinguishment loss in 2024.

Loss from continuing operations increased by $209,873, or 18%, to $1,387,718 in the three months ended March 31, 2024, compared to $1,177,845 in the three months ended March 31, 2023. The increased loss was due primarily a decrease in revenue, offset in part by reduced practice operating costs and corporate overhead costs.

37

*Gain (loss) from operations of discontinued operations*

As a result of the AHP Sale on January 17, 2023, our ACO/MSO Division was classified as discontinued operations in the accompanying consolidated statement of operations for the three months ended March 31, 2024 and 2023. Loss from operations of discontinued operations decreased by $44,289, or 100%, from $44,289 in the three months ended March 31, 2023 to $-0- in the three months ended March 31, 2024. The loss in 2023 reflects two weeks of operations in 2023 as well as winding down costs of the discontinued operation after the sale on January 17, 2023. No revenue or costs were incurred related to the business in the three months ended March 31, 2024.

Effective January 17, 2023, we completed the AHP Sale, at which time we discontinued the operations of CHM and ceased to have a controlling financial interest in AHP. In connection with the AHP Sale, as of January 17, 2023, we recognized the fair value of consideration received and receivable from the AHP Sale, recognized an indemnification liability related to potential claims resulting from the AHP Sale, derecognized the carrying value of assets and liabilities transferred to the Buyer or otherwise derecognized in connection with in the AHP Sale, and recorded a gain on sale for the excess of consideration received over carrying value of assets derecognized and liabilities recognized. Accordingly, we recorded a gain from disposal of AHP in the amount of $2,674,069 in the three months ended March 31, 2023.

*Net loss*

Net income (loss) decreased by $2,839,653, or 196%, to net loss of ($1,387,718) in the three months ended March 31, 2024, compared to net income of $1,451,93 in the three months ended March 31, 2023, primarily as a result of (i) the gain from disposal of AHP in the amount of $2,674,069 in the three months ended March 31, 2023 with no corresponding gain in the three months ended March 31, 2024, and (ii) lower revenue in 2024, offset by (iii) reduced practice operating costs and corporate overhead costs.

**Seasonal Nature of Operations**

We do not experience any material seasonality related to any of our continuing operations.

**Liquidity and Capital Resources**

Liquidity Condition

During the second quarter of 2014, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This update provided U.S. GAAP guidance on management’s responsibility in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and about related footnote disclosures. Under this standard, we are required to evaluate whether there is substantial doubt about our ability to continue as a going concern each reporting period, including interim periods. In evaluating our ability to continue as a going concern, management considered the conditions and events that could raise substantial doubt about our ability to continue as a going concern within 12 months after our financial statements were issued (May 15, 2025).

Management considered our current financial condition and liquidity sources, including current funds available, forecasted future cash flows and our obligations due before May 15, 2025 and concluded that, without additional funding, we will not have sufficient funds to meet our obligations within one year from the date the consolidated financial statements were issued. Without raising additional capital, either via additional advances made pursuant to the SEPA or from other sources, there is substantial doubt about our ability to continue as a going concern through May 15, 2025. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern. This basis of presentation contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business.

We are subject to a number of risks, including uncertainty related to product development and generation of revenues and positive cash flow from our Digital Healthcare Division and a dependence on outside sources of capital. The attainment of profitable operations is dependent on future events, including obtaining adequate financing to fulfill our growth and operating activities and generating a level of revenues adequate to support our cost structure.

As of March 31, 2024, we had cash balances of $23,491, a working capital deficit of $798,224 and an accumulated deficit of $43,420,854. For the three months ended March 31, 2024, we had a net loss of $1,387,718 and we used cash from operating activities of $854,855. We expect to continue to incur net losses and have significant cash outflows for at least the next 12 months.

38

Significant Liquidity Transactions

Through March 31, 2024, we have funded our operations principally through a combination of sales of our common stock, convertible and non-convertible promissory notes, government issued debt, and related party debt, as described below.

On July 5, 2022, we entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, Ltd. (“Yorkville”). Pursuant to the SEPA, we have the right to sell to Yorkville up to 30,000,000 shares of our common stock, par value $0.0001 per share, at our request any time during the three-year commitment period set forth in the SEPA. Because the purchase price per share to be paid by Yorkville for the shares of common stock sold by us to Yorkville pursuant to the SEPA, if any, will fluctuate based on the market prices of our common stock during the applicable pricing period, we cannot reliably predict the actual purchase price per share to be paid by Yorkville for those shares, or the actual gross proceeds we will receive from those sales, if any. During the three months ended March 31, 2023, we sold 225,000 shares of common stock under the SEPA, receiving $18,765 in proceeds, all of which was applied to the balance of a then-outstanding promissory note payable to Yorkville. We have not sold any additional shares under the SEPA since January 2023.

During the three months ended March 31, 2024, we issued three new convertible notes payable to our CEO, Dr. Michael Dent, for aggregate net cash proceeds of $500,000 and refinancing of an existing note in the amount of $166,500. We also made cash repayments on notes payable totaling $221,278.

During the three months ended March 31, 2024, the Company sold 5,100,000 shares of common stock to three investors in separate private placement transactions. The Company received $355,000 in proceeds from the sale. In connection with the stock sale, the Company also issued 2,500,000 five-year warrants to purchase shares of common stock at an exercise price of $0.17 per share.

On January 17, 2023, we entered into the AHP Merger Agreement, pursuant to which the Buyer agreed to buy, and we agreed to sell, AHP. We received $750,000 upon signing of the AHP Merger Agreement, $31,381 in March 2023 for the Stub Period Reimbursement, $1,750,000 ($1,540,000 net after commissions) in Incremental Cash Consideration during June, July and August for meeting participating physician transfer milestones, and $1,873,993 gross ($1,186,231 net after commissions) in October 2023 from the 2022 MSSP Consideration. We may receive future proceeds comprised of proceeds from sale of shares of the Buyer if the Buyer completes an initial public offering by February 1, 2025 and up to $500,000 of the Physician Advance Consideration from the Buyer’s plan year 2023 (and if necessary, 2024) MSSP Shared Savings.

Without raising additional capital, whether via additional advances made pursuant to the SEPA, from the sale of equity or debt instruments, from receipt of remaining contingent consideration related to the sale of the ACO/MSO Division, or from other sources, there is substantial doubt about the Company’s ability to continue as a going concern through May 15, 2025. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of presentation contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

Plan of operation and future funding requirements

Our plan of operations is to profitably operate our Health Services business and continue to invest in our Digital Healthcare business, including our cloud-based online personal medical information and record archiving system, the “HealthLynked Network.”

We are marketing the HealthLynked Network by targeting large health systems, hospitals and universities. In addition, we are marketing via direct-to-patient marketing, affiliated marketing campaigns, co-marketing with our Medical Distribution businesses subsidiary MOD, and expanded southeast regional sales efforts. Our initial sales strategy is utilizing Internet-based marketing to increase penetration to targeted geographical areas. These campaigns are focused on both physician practices and patient members. We also are leveraging MOD’s discounted medical supplies as an offering to our patient and physician members in the HealthLynked Network. We also intend to utilize physician telesales through the use of telesales representatives whom we will hire as access to capital allows. If we fail to complete the development of, or successfully market, the HealthLynked Network, our ability to realize future increases in revenue and operating profits could be impacted, and our results of operations and financial position would be materially adversely affected.

We plan to raise additional capital to fund our ongoing plan of operation.

39

Historical Cash Flows

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | | | | | |  |
|  |  | **2024** | |  |  | **2023** | |  |
| Net cash (used in) provided by: |  |  | |  |  |  | |  |
| Net cash used in continuing operating activities |  | $ | (854,855 | ) |  | $ | (1,052,350 | ) |
| Net cash used in discontinued operating activities |  |  | --- |  |  |  | (47,163 | ) |
| Net cash used in operating activities |  |  | (854,855 | ) |  |  | (1,099,513 | ) |
|  |  |  |  |  |  |  |  |  |
| Net cash provided by (used in) continuing investing activities |  |  | (2,598 | ) |  |  | 781,381 |  |
| Net cash provided by (used in) discontinued investing activities |  |  | --- |  |  |  | --- |  |
| Net cash provided by (used in) investing activities |  |  | (2,598 | ) |  |  | 781,381 |  |
|  |  |  |  |  |  |  |  |  |
| Net cash provided by continuing financing activities |  |  | 633,722 |  |  |  | 324,907 |  |
| Net cash provided by discontinued financing activities |  |  | --- |  |  |  | --- |  |
| Net cash provided by financing activities |  |  | 633,722 |  |  |  | 324,907 |  |
|  |  |  |  |  |  |  |  |  |
| Net increase (decrease) in cash from continuing operating |  |  | (223,731 | ) |  |  | 53,938 |  |
| Net (decrease) in cash from discontinued operating |  |  | --- |  |  |  | (47,163 | ) |
| Net increase (decrease) in cash |  | $ | (223,731 | ) |  | $ | 6,775 |  |

*Operating Activities* – During the three months ended March 31, 2024, we used cash from operating activities of $854,855, as compared with $1,099,513 in the three months ended March 31, 2023. The decrease in cash usage results primarily from cost reduction efforts at our Health Services practices, as well as a decrease of $47,163 in cash used in operations of our discontinued ACO/MSO Division resulting from the unit being sold on January 17, 2023.

*Investing Activities* – During the three months ended March 31, 2024, we used $2,598 in investing activities related to acquisition of computers and office equipment. During the three months ended March 31, 2023, we realized $781,381 from investing activities, comprised of cash proceeds received form the AHP sale, including $750,000 Upfront Cash Consideration and $31,381 Stub Period Reimbursement.

*Financing Activities* – During the three months ended March 31, 2024, cash provided by financing activities was $633,722, comprised of $355,000, from the sale of common stock and $500,000 from the issuance of notes payable to related parties, offset by $221,278 repayments made against notes payable balances. During the three months ended March 31, 2023, cash provided by financing activities was $324,907, comprised of $200,000 from the sale of common stock (net of $18,765 received from sales of common stock under the SEPA that were applied to the balance of a note payable) and $555,000 from the issuance of notes payable, offset by $430,393 repayments made against notes payable balances (net of $18,765 received from sales of common stock under the SEPA that were applied to the balance of a note payable).

**Exercise of Warrants and Options**

No warrants or options were exercised during the three months ended March 31, 2024 or 2023.

**Other Outstanding Obligations at March 31, 2024**

As of March 31, 2024, 85,357,246 shares of our common stock are issuable pursuant to the exercise of warrants with exercise prices ranging from $0.035 to $1.05.

As of March 31, 2024, 9,148,730 shares of our common stock are issuable pursuant to the exercise of options with exercise prices ranging from $0.0569 to $0.31.

As of March 31, 2024, 1,026,324 shares of our common stock are issuable pursuant to future vesting of stock grants.

As of March 31, 2024, 1,055,536 shares of our common stock are earned but unissued pursuant to consulting and director agreements.

40

**Off Balance Sheet Arrangements**

We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable Securities and Exchange Commission rules.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 229.10(f)(1).

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of March 31, 2024 based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. Based on that evaluation, and in light of the material weaknesses found in our internal controls over financial reporting, our management concluded that our disclosure controls and procedures were not effective as of March 31, 2024.

**Changes in Internal Control over Financial Reporting**

There was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the fiscal quarter ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

41

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

We are not aware of any such legal proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

**Item 1A. Risk Factors**

The Company is not required to provide the information required by this item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

Except as previously disclosed in a Current Report on Form 8-K or in a Form 10-Q or 10-K, or as set forth below, the Company has not sold securities that were not registered under the Securities Act of 1933, as amended (the “Securities Act”), during the period covered by this report:

On March 27, 2024, we issued to a trust controlled by Dr. Michael Dent three separate notes payable as follows: (1) a note payable with a principal of $350,000, an interest rate of 12% per annum, and a maturity date of June 27, 2024, (2) a note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of August 24, 2024, and (3) a note payable with a principal of $166,500, an interest rate of 12% per annum, and a maturity date of August 28, 2024 (collectively, the “March 2024 Dent Notes”). The full amount of principal and accrued interest on each of the March 2024 Dent Notes is due at the respective maturity date of each note. Each of the March 2024 Dent Notes is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.0573 per share, or 11,631,762 shares.

On March 29, 2024, we issued 6,660,000 ten-year warrants with an exercise price of $0.06 per share that were attached to a convertible note payable.

On April 10, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of October 10, 2024. The convertible note payable is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.0577, or 2,599,653 shares.

On April 12, 2024, we sold 877,193 shares of common stock for cash in a private placement transaction to an accredited investor. We received $50,000 in proceeds from the sale. In connection with the stock sale, we also issued 438,596 five-year warrants to purchase shares of common stock at an exercise price of $0.16 per share

On April 18, 2024, we issued to a trust controlled by Dr. Michael Dent a convertible note payable with a principal of $150,000, an interest rate of 12% per annum, and a maturity date of October 18, 2024. The convertible note payable is convertible at any time at the holder’s option into shares of our common stock at a fixed conversion price of $0.05 per share, or 1,000,000 shares.

The sales of the above securities were exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act, as transactions by an issuer not involving any public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions.

42

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

**Item 6. Exhibits**

|  |  |  |
| --- | --- | --- |
| **Exhibit No.** |  | **Exhibit Description** |
| 31.1\* |  | [Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer](file:////var/opt/apache-tomcat/temp/ea020559401ex31-1_health.htm) |
| 31.2\* |  | [Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer](file:////var/opt/apache-tomcat/temp/ea020559401ex31-2_health.htm) |
| 32.1\* |  | [Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Executive Officer](file:////var/opt/apache-tomcat/temp/ea020559401ex32-1_health.htm) |
| 32.2\* |  | [Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of the Principal Financial Officer and Principal Accounting Officer](file:////var/opt/apache-tomcat/temp/ea020559401ex32-2_health.htm) |
| 101.INS\* |  | Inline XBRL Instance Document. |
| 101.SCH\* |  | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL\* |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.DEF\* |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101.LAB\* |  | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE\* |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104\* |  | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |

|  |  |  |
| --- | --- | --- |
|  | \* | Filed herewith. |

43

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: May 15, 2024

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HEALTHLYNKED CORP.** | | |
|  |  | | |
|  | By: | /s/ Michael Dent | |
|  |  | Name: | Michael Dent |
|  |  | Title: | Chief Executive Officer and Chairman  (Principal Executive Officer) |

|  |  |  |  |
| --- | --- | --- | --- |
|  | By: | /s/ David Rosal | |
|  |  | Name: | David Rosal |
|  |  | Title: | Chief Financial Officer  (Principal Financial Officer) |

44